<XBRL>
<?xml version="1.0" encoding="UTF-8"?><!--EDGARizerX:  Instance document generated by EDGARizerX, version 3.5.3.1--><xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:asi="http://regeneron.com/20110216" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://xbrl.us/us-gaap/2009-01-31" xmlns:regn="http://regeneron.com/20101231" xmlns:dei="http://xbrl.us/dei/2009-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="regn-20101231.xsd"/>
  <context id="c00000">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00001">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00002">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00004">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00005">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00006">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c00007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c00014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c00021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00024">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00025">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00026">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00027">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c00028">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c00029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c00030">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c00031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c00032">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c00033">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c00034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00035">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00037">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00038">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00039">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c00041">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00042">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00043">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00045">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00046">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00047">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c00048">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
    </entity>
    <period>
      <instant>2011-02-11</instant>
    </period>
  </context>
  <unit id="u000">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="u001">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Convertible Debt-->
  <us-gaap:DebtDisclosureTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;10.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Convertible Debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In October 2001, the Company issued $200.0 million aggregate principal amount of convertible senior subor
dinated notes (&amp;#8220;Notes&amp;#8221;) in a private placement for proceeds to the Company of $192.7 million, after deducting the initial purchasers&amp;#8217; discount and out-of-pocket expenses (collectively, &amp;#8220;Deferred Financing Costs&amp;#8221;).&amp;#160;&amp;#160;The Notes bore interest at 5.5% per annum, payable semi-annually, and matured on October 17, 2008.&amp;#160;&amp;#160;Deferred Financing Costs, which were included in other assets, were amortized as interest expense over the period from the Notes&amp;#8217; issuance to stated maturity.&amp;#160;&amp;#160;During the second and third quarters of 2008, the Company repurchased $82.5 million in principal amount of the Notes for $83.3 million and recognized a $0.9 million loss on early extinguishment of debt, representing the premium paid on the Notes plus related unamortized Deferred Financing Costs.&amp;#160;&amp;#160;The remaining $117.5 million of outstanding Notes were repaid in full upon their maturity in October 2008.&lt;/font&gt
;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <!--ARCALYST (rilonacept) Product Revenue-->
  <regn:ArcalystRilonaceptProductRevenue contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;5.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"&gt;&amp;#210;&lt;/font&gt; Product Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10
pt; FONT-FAMILY: Times New Roman"&gt;In February 2008, the Company received marketing approval from the FDA for ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; Injection for Subcutaneous Use for the treatment of CAPS.&amp;#160;&amp;#160;The Company had limited historical return experience for ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; beginning with initial sales in 2008 through the end of 2009; therefore, ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales were deferred until the right of return no longer existed and rebates could be reasonably estimated.&amp;#160;&amp;#160;Effective in the first quarter of 2010, the Company determined that it had accumulated sufficient historical data to reasonably estimate both product returns and rebates of ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTIC
AL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;.&amp;#160;&amp;#160;As a result, $4.8 million of previously deferred ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales were recognized as revenue in the first quarter of 2010.&amp;#160;&amp;#160;The effect of this change in estimate related to ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales revenue was to lower the Company&amp;#8217;s net loss per share by $0.06 in 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales totaled $25.3 million, $18.
4 million, and $6.3 million for the years ended December 31, 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174; &lt;/font&gt;net product sales during 2010 included $20.5 million of net product sales made during this period and $4.8 million of previously deferred net product sales, as described above.&amp;#160;&amp;#160;There was no deferred ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales revenue at December 31, 2010.&amp;#160;&amp;#160;At December 31, 2009, deferred ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales revenue was $4.8 million.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font st
yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;Cost of goods sold related to ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; sales, which consisted primarily of royalties and other period costs, totaled $2.1 million, $1.7 million, and $0.9 million for the years ended December 31, 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;To date, ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; shipments to the Company&amp;#8217;s customers have primarily consisted of supplies of inventory manufactured and expensed as research and development costs prior to 2008; therefore, the costs of these supplies were not included in costs of goods sold.&amp;#160;&amp;#160;Inventories related to ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;, which were included in prepaid expenses and other curre
nt assets, consisted of $0.7 million of work-in-process and $0.1 million of finished goods at December 31, 2010, and $0.4 million of work-in-process at December 31, 2009.&lt;/font&gt;&lt;/div&gt;</regn:ArcalystRilonaceptProductRevenue>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c00041">No</dei:EntityVoluntaryFilers>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c00041">FY</dei:DocumentFiscalPeriodFocus>
  <!--Issuance of Common Stock in a public offering, net of issuance costs - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="u000" decimals="-3" contextRef="c00042">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Issuance of Common Stock in a public offering, net of issuance costs - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="u000" decimals="-3" contextRef="c00043">174822000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Issuance of Common Stock in a public offering, net of issuance costs - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="u000" decimals="-3" contextRef="c00041">174828000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00006">-284000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00013">1158000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Change in net unrealized gain (loss) on marketable securities - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00047">-3535000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00000">-284000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00007">1158000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Total Stockholders' Equity + Change in net unrealized gain (loss) on marketable securities - Total Stockholders' Equity-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00041">-3535000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00005">-284000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00012">1158000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.7 million - Comprehensive Loss- Comprehensive Loss [Member] + Change in net unrealized gain (loss) on marketable securities - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="u000" decimals="-3" contextRef="c00046">-3535000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Net decrease in cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="u000" decimals="-3" contextRef="c00041">-94503000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Net decrease in cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="u000" decimals="-3" contextRef="c00007">-40721000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Net decrease in cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="u000" decimals="-3" contextRef="c00000">-251129000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Sales or maturities of marketable securities-->
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities unitRef="u000" decimals="-3" contextRef="c00041">276601000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <!--Sales or maturities of marketable securities-->
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities unitRef="u000" decimals="-3" contextRef="c00007">297411000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <!--Sales or maturities of marketable securities-->
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities unitRef="u000" decimals="-3" contextRef="c00000">646861000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <!--Net loss per share, basic and diluted-->
  <regn:NetLossPerShareBasicAndDiluted unitRef="u000" decimals="2" contextRef="c00041">-1.26</regn:NetLossPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted-->
  <regn:NetLossPerShareBasicAndDiluted unitRef="u000" decimals="2" contextRef="c00007">-0.85</regn:NetLossPerShareBasicAndDiluted>
  <!--Net loss per share, basic and diluted-->
  <regn:NetLossPerShareBasicAndDiluted unitRef="u000" decimals="2" contextRef="c00000">-1.00</regn:NetLossPerShareBasicAndDiluted>
  <!--Total expenses-->
  <us-gaap:CostsAndExpenses unitRef="u000" decimals="-3" contextRef="c00041">556546000</us-gaap:CostsAndExpenses>
  <!--Total expenses-->
  <us-gaap:CostsAndExpenses unitRef="u000" decimals="-3" contextRef="c00007">453371000</us-gaap:CostsAndExpenses>
  <!--Total expenses-->
  <us-gaap:CostsAndExpenses unitRef="u000" decimals="-3" contextRef="c00000">324706000</us-gaap:CostsAndExpenses>
  <!--Preferred stock, shares outstanding-->
  <us-gaap:PreferredStockSharesOutstanding unitRef="u001" decimals="0" contextRef="c00034">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding-->
  <us-gaap:PreferredStockSharesOutstanding unitRef="u001" decimals="0" contextRef="c00021">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Marketable securities-->
  <us-gaap:MarketableSecuritiesNoncurrent unitRef="u000" decimals="-3" contextRef="c00034">370053000</us-gaap:MarketableSecuritiesNoncurrent>
  <!--Marketable securities-->
  <us-gaap:MarketableSecuritiesNoncurrent unitRef="u000" decimals="-3" contextRef="c00021">47080000</us-gaap:MarketableSecuritiesNoncurrent>
  <!--Accounts receivable from the sanofi-aventis Group-->
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="u000" decimals="-3" contextRef="c00034">79603000</us-gaap:DueFromRelatedPartiesCurrent>
  <!--Accounts receivable from the sanofi-aventis Group-->
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="u000" decimals="-3" contextRef="c00021">62703000</us-gaap:DueFromRelatedPartiesCurrent>
  <!--Unaudited Quarterly Results-->
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;20.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Unaudited Quarterly Results&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Summarized quarterly financial data for the years ended December 31, 2010 and 2
009 are set forth in the following tables.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;First Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="c
enter"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;March 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Second Quarter &lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;June 30, 2010&
lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Third Quarter &lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;E&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;nded&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;September 30, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td
&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="17%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Fourth Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/f
ont&gt;&lt;/td&gt;&lt;td valign="top" width="64%" colspan="4"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;$103,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-R
IGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$115,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$105,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="17%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$133,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign
="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;(30,522)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;(25,474)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;(33,875)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="17%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR
GIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;(14,597)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Net loss per share, basic and diluted:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA
MILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$(0.38)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.31)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.41)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="17%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLA
Y: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;$(0.17)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;First Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: 
inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;March 31, 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Second Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;June 30, 2009&lt;/font&gt;&lt;/font&gt;&lt;/
div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Third Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;September 30, 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="17%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Fourth Quarter&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT
- -INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;December 31, 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="64%" colspan="4"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&l
t;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;$74,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$90,032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Ti
mes New Roman"&gt;$117,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="17%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$96,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;(15,388)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; T
EXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;(14,938)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;(1,015)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="17%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;(36,489)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="20%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: 
inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Net loss per share, basic and diluted:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$(0.19)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE
: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.19)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="16%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;$(0.01)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="17%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;$(0.46)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformat
ionTextBlock>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c00041">false</dei:AmendmentFlag>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="u001" decimals="-3" contextRef="c00001">980000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="u001" decimals="-3" contextRef="c00008">1134000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="u001" decimals="-3" contextRef="c00042">1533000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Cost of goods sold-->
  <us-gaap:CostOfGoodsSold unitRef="u000" decimals="-3" contextRef="c00041">2093000</us-gaap:CostOfGoodsSold>
  <!--Cost of goods sold-->
  <us-gaap:CostOfGoodsSold unitRef="u000" decimals="-3" contextRef="c00007">1686000</us-gaap:CostOfGoodsSold>
  <!--Cost of goods sold-->
  <us-gaap:CostOfGoodsSold unitRef="u000" decimals="-3" contextRef="c00000">923000</us-gaap:CostOfGoodsSold>
  <!--Technology licensing-->
  <us-gaap:LicensesRevenue unitRef="u000" decimals="-3" contextRef="c00041">40150000</us-gaap:LicensesRevenue>
  <!--Technology licensing-->
  <us-gaap:LicensesRevenue unitRef="u000" decimals="-3" contextRef="c00007">40013000</us-gaap:LicensesRevenue>
  <!--Technology licensing-->
  <us-gaap:LicensesRevenue unitRef="u000" decimals="-3" contextRef="c00000">40000000</us-gaap:LicensesRevenue>
  <!--Deferred revenue - other-->
  <us-gaap:DeferredRevenueNoncurrent unitRef="u000" decimals="-3" contextRef="c00034">188775000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue - other-->
  <us-gaap:DeferredRevenueNoncurrent unitRef="u000" decimals="-3" contextRef="c00021">46951000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue from sanofi-aventis, current portion-->
  <regn:DeferredRevenueFromRelatedPartyCurrent unitRef="u000" decimals="-3" contextRef="c00034">19506000</regn:DeferredRevenueFromRelatedPartyCurrent>
  <!--Deferred revenue from sanofi-aventis, current portion-->
  <regn:DeferredRevenueFromRelatedPartyCurrent unitRef="u000" decimals="-3" contextRef="c00021">17523000</regn:DeferredRevenueFromRelatedPartyCurrent>
  <!--Property, plant, and equipment, at cost, net of accumulated  depreciation and amortization-->
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="u000" decimals="-3" contextRef="c00034">347450000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, plant, and equipment, at cost, net of accumulated  depreciation and amortization-->
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="u000" decimals="-3" contextRef="c00021">259676000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Organization and Business-->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;1.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Organization and Business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Regeneron Pharmaceuticals, Inc. (the &am
p;#8220;Company&amp;#8221; or &amp;#8220;Regeneron&amp;#8221;) was incorporated in January 1988 in the State of New York.&amp;#160;&amp;#160;The Company is engaged in the research, development, and commercialization of pharmaceutical products for the treatment of serious medical conditions.&amp;#160;&amp;#160;In 2008, the Company received marketing approval from the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) for the Company&amp;#8217;s first commercial drug product, ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"&gt;&amp;#210;&lt;/font&gt; (rilonacept) Injection for Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes (&amp;#8220;CAPS&amp;#8221;).&amp;#160;&amp;#160;The Company's facilities are primarily located in New York.&amp;#160;&amp;#160;The Company&amp;#8217;s business is subject to certain risks including, but not limited to, uncertainties relating to conducting pharmaceutical research, obtainin
g regulatory approvals, commercializing products, and obtaining and enforcing patents.&lt;/font&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c00041">Yes</dei:EntityWellKnownSeasonedIssuer>
  <!--Issuance of Common Stock in a public offering, net of issuance costs - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="u001" decimals="-3" contextRef="c00042">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Marketable Securities-->
  <us-gaap:MarketableSecuritiesTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;6.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Marketable securities at December 31, 2010 and 2009 consisted of debt securities, as detailed b
elow, and equity securities, the aggregate fair value of which was $3.6 million and $5.5 million at December 31, 2010 and 2009, respectively, and the aggregate cost basis of which was $4.0 million at both December 31, 2010 and 2009.&amp;#160;&amp;#160;The Company also held restricted marketable securities at December 31, 2010, which consisted of debt securities, as detailed below, that collateralize (i) a letter of credit in connection with the Company&amp;#8217;s lease of facilities in Tarrytown, New York and (ii) capital lease obligations.&amp;#160;&amp;#160;See Note 11a.&amp;#160;&amp;#160;The Company held no restricted marketable securities at December 31, 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The following tables summarize the amortized cost basis of 
debt securities included in marketable securities, the aggregate fair value of those securities, and gross unrealized gains and losses on those securities at December 31, 2010 and 2009.&amp;#160;&amp;#160;The Company classifies its debt securities, other than mortgage-backed securities, based on their contractual maturity dates.&amp;#160;&amp;#160;Maturities of mortgage-backed securities have been estimated based primarily on repayment characteristics and experience of the senior tranches that the Company holds.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; F
ONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;Fair&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" colspan="3"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" 
align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;Cost Basis&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&lt;font st
yle="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Gains&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;(Losses)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" wi
dth="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Net&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new r
oman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style
="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" alig
n="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$83,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$83,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%" colspan="2"
&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;48,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: 
inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;48,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: 
inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11
%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" wid
th="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISP
LAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;875&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;847&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="
right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(28)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(28)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td val
ign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;136,307&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;136,796&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT
: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;522&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(33)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;489&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="D
ISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Maturities between one and five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&
lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;352,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;350,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;fon
t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(1,726)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(1,662)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td 
valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;15,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;15,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right"
 width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;110&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div sty
le="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;38&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(72)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width
="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(72)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;367,977&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="righ
t" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;366,198&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;64&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(1,843)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(1,779)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Maturities between five and seven years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" 
width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new 
roman"&gt;&lt;font style="DISPLAY: inline"&gt;284&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;243&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FO
NT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(41)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(41)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;504,568&lt;/font&gt;&lt;/font&gt;&lt;/div&gt
;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;503,237&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;586&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font 
style="DISPLAY: inline"&gt;(1,917)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(1,331)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10p
t; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td v
align="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim
es new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline
; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 
times new roman"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&l
t;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Maturities between one and three years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMI
LY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;4,135&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font 
style="DISPLAY: inline"&gt;4,118&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(17)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F
AMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(17)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;7,057&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;t
d style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/f
ont&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" w
idth="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$511,625&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$510,276&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;
 MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$586&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,935)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(1,349)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font s
tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" wi
dth="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="31%" colspan="3"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SI
ZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT
: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td vali
gn="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Maturities within one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#1
60; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$100,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$100,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT:
 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MA
RGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;17,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;17,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE
XT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;10,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;10,342&lt;/font&gt;&lt
;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed coll
ateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&
amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;2,471&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td styl
e="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;2,338&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(133)&lt;/font&gt;&lt;/font&gt;&lt;/div
&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(133)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;133,892&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;
div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;134,255&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;496&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(133)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BO
TTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;363&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Maturities between one and two years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style=
"DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;9,413&lt;/font&gt;&lt;/div&gt;&lt;/td&gt
;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;9,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(46)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(46)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td val
ign="top" align="left" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;31,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;31,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;
font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0p
t; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;1,168&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;900&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY:
 block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(268)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(268)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="D
ISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;41,645&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;41,611&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;280&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 
2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(314)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(34)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt
;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="30%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: 
inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$175,537&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$175,866&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$776&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE
XT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(447)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$329&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;At December 31, 2010 and 2009, marketable securities included an additional unrealized loss of $0.4 million and an addi
tional unrealized gain of $1.4 million, respectively, related to one equity security in the Company&amp;#8217;s marketable securities portfolio.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The following table shows the fair value of the Company&amp;#8217;s marketable securities that have unrealized losses and that are deemed to be only temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position, at December 31, 2010 and 2009.&amp;#160;&amp;#160;The debt securities listed at December 31, 2010, excluding mortgage-backed securities, mature at various dates through November 2013.&amp;#160;&amp;#160;The mortgage-backed securities listed at December 31, 2010 mature at various da
tes through January 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="20%" colspan="2"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;Less than 12 Months&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="19%" colspan="2"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARG
IN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;12 Months or Greater&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="20%" colspan="2"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="24%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;fon
t style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDEN
T: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style
="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&
lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Unrealized &lt;font style="DISPLAY: inline"&gt;Loss&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPL
AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;f
ont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$340,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$(1,731)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$340,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" 
width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$(1,731)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 
times new roman"&gt;19,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;19,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGI
N-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(45)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(433)&lt;/font
&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(433)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt;
 MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&
lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: bloc
k; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;363,061&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: blo
ck; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(2,209)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2
px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;364,189&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(2,350)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td
&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new r
oman"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%
"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td
&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td 
style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN
- -LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; 
TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;6,154&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(18)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time
s new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="rig
ht"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$369,215&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(2,227)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$1,128&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div styl
e="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(141)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$370,343&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(2,368)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;
tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ti
mes new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&
gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&l
t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$9,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign=
"top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$(46)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$9,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPL
AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$(46)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&a
mp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$3,238&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(401)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 
times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;3,238&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(401)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="24%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 
times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$9,367&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(46)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$3,238&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt
" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(401)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$12,605&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$(447)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;
br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Realized gains and losses are included as a component of investment income.&amp;#160;&amp;#160;For the year ended December 31, 2010, realized losses on sales of marketable securities totaled $0.2 million and realized gains on sales of marketable securities were not significant.&amp;#160;&amp;#160;For the years ended December 31, 2009 and 2008, realized gains on sales of marketable securities totaled $0.2 million and $1.2 million, respectively, and realized losses on sales of marketable securities were not significant.&amp;#160;&amp;#160;In computing realized gains and losses, the Company computes the cost of its investments on a specific identification basis.&amp;#160;&amp;#160;Such cost includes the direct costs to acquire the security, adjusted for the amortization of any discount or premium.&lt;/font
&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company&amp;#8217;s assets that are measured at fair value on a recurring basis&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;,&lt;/font&gt; at December 31, 2010 and 2009, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIG
N: center" valign="top" width="39%" colspan="3"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value Measurements at Reporting Date Using&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Quoted Prices in Active &lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Markets for Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 1)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-I
NDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Significant Other Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 2)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Significant Unobservable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; 
FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(Level 3)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" 
width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"&gt;Unrestricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&
gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top
" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$434,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$434,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" wi
dth="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;64,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; 
MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;64,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline;
 FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-S
IZE: 10pt; FONT-FAMILY: times new roman"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="r
ight" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font styl
e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI
GHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;506,849&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIG
HT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;503,237&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#1
60; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-
SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td vali
gn="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="top" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td 
style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;7,039&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: 
inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$513,888&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$3,612&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$510,276&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#16
0; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;At December 31, 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline;
 FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Available-for-sale marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government obligations
&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$109,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$109,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt
; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;48,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;48,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FO
NT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;10,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: t
imes new roman"&gt;10,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;U.S. government guaranteed collateralized mortgage obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="botto
m" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Mortgage-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign
="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Equity security&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDE
NT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;5,469&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$5,469&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new rom
an"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$181,335&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$5,469&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="
right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$175,866&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Marketable securities included in Level 2 were valued using a market approach utilizing prices and other relevant information, such as interest rates, yield curves, prepayment speeds, loss severities, credit risks and default rates, generated by market transaction
s involving identical or comparable assets.&amp;#160;&amp;#160;The Company considers market liquidity in determining the fair value for these securities.&amp;#160;&amp;#160;During each of the years ended December 31, 2010 and 2008, deterioration in the credit quality of a marketable security subjected the Company to the risk of not being able to recover the carrying value of these securities.&amp;#160;&amp;#160;As a result, the Company recognized a $0.1 million and $1.8 million impairment charge related to its Level 2 marketable securities for the years ended December 31, 2010 and 2008, respectively, which the Company considered to be other-than-temporarily impaired.&amp;#160;&amp;#160;During the year ended December 31, 2009, the Company did not record any charges for other-than-temporary impairment of its Level 2 marketable securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN
- -RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company held one Level 3 marketable security, which had no fair value at December 31, 2010 and 2009, and whose fair value was $0.1 million at December 31, 2008.&amp;#160;&amp;#160;This Level 3 security was valued using information provided by the Company&amp;#8217;s investment advisors and other sources, including quoted bid prices which took into consideration the securities&amp;#8217; lack of liquidity.&amp;#160;&amp;#160;During the years ended December 31, 2009 and 2008, the Company recorded charges of $0.1 million and $0.7 million, respectively, for other-than-temporary impairment of this Level 3 marketable security; therefore, as of December 31, 2009, the fair value of this security had been written down to zero.&amp;#160;&amp;#160;There were no purchases, sales, or maturities of Level 3 marketable securities and no unrealized gains or losses related to Level 3 marketable securities for
 the years ended December 31, 2010 and 2009.&amp;#160;&amp;#160;There were no transfers of marketable securities between Levels 1, 2, or 3 classifications during the years ended December 31, 2010 and 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;As described in Note 2 above under &amp;#8220;Use of Estimates&amp;#8221;, on a quarterly basis, the Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary.&amp;#160;&amp;#160;With respect to debt securities, this review process also includes an evaluation of the Company&amp;#8217;s (a) intent to sell an individual debt security or (b) need to sell the debt security before its anticipated recovery or
 maturity.&amp;#160;&amp;#160;With respect to equity securities, this review process includes an evaluation of the Company&amp;#8217;s ability and intent to hold the securities until their full value can be recovered.&lt;/font&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
  <!--Document Type-->
  <dei:DocumentType contextRef="c00041">10-K</dei:DocumentType>
  <!--Entity Public Float-->
  <dei:EntityPublicFloat unitRef="u000" decimals="0" contextRef="c00034">1726149000</dei:EntityPublicFloat>
  <!--Cash and cash equivalents at beginning of period + Cash and cash equivalents at end of period-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="u000" decimals="-3" contextRef="c00021">207075000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents at beginning of period + Cash and cash equivalents at end of period-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="u000" decimals="-3" contextRef="c00014">247796000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents at beginning of period + Cash and cash equivalents at end of period-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="u000" decimals="-3" contextRef="c00028">498925000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents at beginning of period + Cash and cash equivalents at end of period-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="u000" decimals="-3" contextRef="c00034">112572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Class A Stock, shares issued- Class A [Member]-->
  <us-gaap:CommonStockSharesIssued unitRef="u001" decimals="0" contextRef="c00035">2182036</us-gaap:CommonStockSharesIssued>
  <!--Class A Stock, shares issued- Class A [Member]-->
  <us-gaap:CommonStockSharesIssued unitRef="u001" decimals="0" contextRef="c00022">2244698</us-gaap:CommonStockSharesIssued>
  <!--Common Stock, shares issued-->
  <us-gaap:CommonStockSharesIssued unitRef="u001" decimals="0" contextRef="c00034">87238301</us-gaap:CommonStockSharesIssued>
  <!--Common Stock, shares issued-->
  <us-gaap:CommonStockSharesIssued unitRef="u001" decimals="0" contextRef="c00021">78860862</us-gaap:CommonStockSharesIssued>
  <!--Preferred stock, par value-->
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="u000" decimals="2" contextRef="c00034">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, par value-->
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="u000" decimals="2" contextRef="c00021">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Prepaid expenses and other current assets-->
  <regn:PrepaidExpensesAndOtherCurrentAssets unitRef="u000" decimals="-3" contextRef="c00034">15142000</regn:PrepaidExpensesAndOtherCurrentAssets>
  <!--Prepaid expenses and other current assets-->
  <regn:PrepaidExpensesAndOtherCurrentAssets unitRef="u000" decimals="-3" contextRef="c00021">18610000</regn:PrepaidExpensesAndOtherCurrentAssets>
  <!--Technology Licensing Agreements-->
  <regn:TechnologyLicensingAgreementTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Technology Licensing Agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In February 2007, the Company entered into a six-year, non-exclusive license agr
eement with AstraZeneca UK Limited to allow AstraZeneca to utilize the Company&amp;#8217;s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"&gt;&amp;#210;&lt;/font&gt; technology in its internal research programs to discover human monoclonal antibodies.&amp;#160;&amp;#160;Under the terms of the agreement, AstraZeneca made a $20.0 million annual, non-refundable payment to the Company in each of 2010, 2009, 2008, and 2007.&amp;#160;&amp;#160;Each annual payment was deferred and recognized as revenue ratably over approximately the ensuing twelve-month period.&amp;#160;&amp;#160;In November 2010, as permitted by the agreement, MedImmune Limited (as successor by novation from AstraZeneca) gave written notice of voluntary termination of the agreement, effective in February 2011, thereby canceling its obligation to make either of the final two annual payments.&amp;#160;&amp;#160;Regen
eron remains entitled to receive mid-single digit royalties on any future sales of antibody products discovered by MedImmune/AstraZeneca using the &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology.&amp;#160;&amp;#160;In connection with the AstraZeneca license agreement, for each of the years ended December 31, 2010, 2009, and 2008, the Company recognized $20.0 million of technology licensing revenue.&amp;#160;&amp;#160;In addition, deferred revenue at December 31, 2010, 2009, and 2008 was $2.9 million.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In March 2007, the Company entered into a six-year, non-exclusive license agreement
 with Astellas Pharma Inc. to allow Astellas to utilize the Company&amp;#8217;s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;&amp;#160;&lt;/font&gt;technology in its internal research programs to discover human monoclonal antibodies.&amp;#160;&amp;#160;Under the terms of the agreement, Astellas made a $20.0 million annual, non-refundable payment to the Company in each of 2010, 2009, 2008, and 2007.&amp;#160;&amp;#160;In July 2010, the license agreement with Astellas was amended and extended through June 2023.&amp;#160;&amp;#160;Under the terms of the amended agreement, Astellas made a $165.0 million up-front payment to the Company in August 2010, which was deferred upon receipt and will be recognized as revenue ratably over the seven-year period beginning in mid-2011.&amp;#160;&amp;#160;In addition, Astellas will make a
 $130.0 million second payment to the Company in June 2018 unless the license agreement has been terminated prior to that date.&amp;#160;&amp;#160;Astellas has the right to terminate the agreement at any time by providing 90 days&amp;#8217; advance written notice.&amp;#160;&amp;#160;Under certain limited circumstances, such as a material breach of the agreement by the Company, Astellas may terminate the agreement and receive a refund of a portion of its up-front payment or, if such termination occurs after June 2018, a portion of its second payment, to the Company under the July 2010 amendment to the agreement.&amp;#160;&amp;#160;The Company is entitled to receive a mid-single-digit royalty on any future sales of antibody products discovered by Astellas using the Company&amp;#8217;s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology.&amp;#160;&amp;#160;In connection wi
th the Astellas license agreement, for each of the years ended December 31, 2010, 2009, and 2008, the Company recognized $20.0 million of technology licensing revenue.&amp;#160;&amp;#160;In addition, deferred revenue at December 31, 2010, 2009, and 2008 was $173.7 million, $8.7 million, and $8.7 million, respectively.&lt;/font&gt;&lt;/div&gt;</regn:TechnologyLicensingAgreementTextBlock>
  <!--Summary of Significant Accounting Policies-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Cash and Cash Equivalents&l
t;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For purposes of the statement of cash flows and the balance sheet, the Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents.&amp;#160;&amp;#160;The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&
lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company has invested its excess cash primarily in direct obligations of the U.S. government and its agencies, other debt securities guaranteed by the U.S. government, and money market funds that invest in U.S. Government securities.&amp;#160;&amp;#160;The Company considers its marketable securities to be &amp;#8220;available-for-sale,&amp;#8221; as defined by authoritative guidance issued by the Finan
cial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;).&amp;#160;&amp;#160;These assets are carried at fair value and the unrealized gains and losses are included in other accumulated comprehensive income (loss) as a separate component of stockholders&amp;#8217; equity.&amp;#160;&amp;#160;If the decline in the value of a marketable security in the Company&amp;#8217;s investment portfolio is deemed to be other-than-temporary, the Company writes down the security to its current fair value and recognizes a loss that may be charged against income.&amp;#160;&amp;#160;As described under &amp;#8220;Use of Estimates&amp;#8221; below, on a quarterly basis, the Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI
GHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Inventories are stated at the lower of cost or estimated realizable value.&amp;#160;&amp;#160;The Company determines the cost of inventory using the first-in, first-out, or FIFO, method.&amp;#160;&amp;#160;The Company capitalizes inventory costs associated with the Company&amp;#8217;s products prior to regulatory approval when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; othe
rwise, such costs are expensed as research and development.&amp;#160;&amp;#160;The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Property, Plant, and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Property, plant, and equipment are stated at cost, net 
of accumulated depreciation.&amp;#160;&amp;#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets.&amp;#160;&amp;#160;Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred.&amp;#160;&amp;#160;The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in operations.&amp;#160;&amp;#160;The estimated useful lives of property, plant, and equipment are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Building and improvements&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160
;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;10-40 years&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Laboratory and other equipment&amp;#160;&amp;#160;&amp;#160;&amp;#1
60;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3-10 years&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 72pt"&gt;&lt;/font&gt;Furniture and fixtures&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp
;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 5 years&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIG
HT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term, without assuming renewal features, if any, are exercised.&amp;#160;&amp;#160;Costs of construction of certain long-lived assets include capitalized interest which is amortized over the estimated useful life of the related asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;&lt;a id="jump_exp_29" name="jump_exp_29"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="jump_exp_30" name="jump_exp_30"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&lt;a id="jump_exp_31" name="jump_exp_31"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a
&gt;&lt;a id="jump_exp_32" name="jump_exp_32"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;Accounting for the Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&amp;#160;&amp;#160;Asset impairment is determined to exist if estimated future undiscounted cash flows are less than the carrying amount.&amp;#160;&amp;#160;For all periods presented, no impairment losses were recorded.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div 
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;As a result of the Company&amp;#8217;s research and development efforts, the Company obtains and applies for patents to protect proprietary technology and inventions.&amp;#160;&amp;#160;All costs associated with patents for product candidates under development are expensed as incurred.&amp;#160;Patent costs related to commercial products are capitalized and amortized over the shorter of their estimated useful life or the remaining patent term.&amp;#160;&amp;#160;To date, the Company has no capitalized 
patent costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;On certain of its operating lease agreements, the Company may receive rent holidays and other incentives. The Company recognizes operating lease costs on a straight-line basis without regard to deferred payment terms, such as rent holidays that defer the commencement date of required payments.&amp;#160;&amp;#160;In addition, lease incentives that the Company receives are tr
eated as a reduction of rent expense over the term of the related agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;a. Collaboration Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"
&gt;The Company earns collaboration revenue in connection with collaboration agreements to develop and commercialize product candidates and utilize the Company&amp;#8217;s technology platforms.&amp;#160;&amp;#160;The terms of these agreements typically include non-refundable up-front licensing payments, research progress (milestone) payments, and payments for development activities.&amp;#160;&amp;#160;Non-refundable up-front license payments, where continuing involvement is required of the Company, are deferred and recognized over the related performance period.&amp;#160;&amp;#160;The Company estimates its performance period based on the specific terms of each agreement, and adjusts the performance periods, if appropriate, based on the applicable facts and circumstances.&amp;#160;&amp;#160;Payments which are based on achieving a specific performance milestone, involving a degree of risk, are recognized as revenue when the milestone is achieved and the related payment is due and non-refundable, provided there
 is no future service obligation associated with that milestone.&amp;#160; Substantive performance milestones typically consist of significant achievements in the development life-cycle of the related product candidate, such as completion of clinical trials, filing for approval with regulatory agencies, and receipt of approvals by regulatory agencies.&amp;#160;&amp;#160;In determining whether a payment is deemed to be a substantive performance milestone, the Company takes into consideration (i) the nature, timing, and value of significant achievements in the development life-cycle of the related development product candidate, (ii) the relative level of effort required to achieve the milestone, and (iii) the relative level of risk in achieving the milestone, taking into account the high degree of uncertainty in successfully advancing product candidates in a drug development program and in ultimately attaining an approved drug product.&amp;#160; Payments for achieving milestones which are not considered substa
ntive are accounted for as license payments and recognized over the related performance period.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company enters into collaboration agreements that include varying arrangements regarding which parties perform and bear the costs of research and development activities.&amp;#160;&amp;#160;The Company may&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;share the costs of research and development activities with a collaborator, such as in the Company&amp;#8217;s VEGF Trap-Eye collaboration with Bayer HealthCare LLC, or the Company may be reimbursed for all or a significant portion of the costs of the Company&amp;#8217;s research and development activities, such as in the Company&amp;#8217;s afliberc
ept and antibody collaborations with the sanofi-aventis Group.&amp;#160;&amp;#160;The Company records its internal and third-party development costs associated with these collaborations as research and development expenses.&amp;#160;&amp;#160;When the Company is entitled to reimbursement of all or a portion of the research and development expenses that it incurs under a collaboration, the Company records those reimbursable amounts as collaboration revenue proportionately as the Company recognizes its expenses.&amp;#160;&amp;#160;If the collaboration is a cost-sharing arrangement in which both the Company and its collaborator perform development work and share costs, in periods when the Company&amp;#8217;s collaborator incurs development expenses that benefit the collaboration and Regeneron, the Company also recognizes, as additional research and development expense, the portion of the collaborator&amp;#8217;s development expenses that the Company is obligated to reimburse.&lt;/font&gt;&lt;/div&gt;&lt;div sty
le="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In connection with non-refundable licensing payments, the Company&amp;#8217;s performance period estimates are principally based on projections of the scope, progress, and results of its research and development activities.&amp;#160;&amp;#160;Due to the variability in the scope of activities and length of time necessary to develop a drug product, changes to development plans as programs progress, and uncertainty in the ultimate requirements to obtain governmental approval for commercialization, revisions to performance period estimates are likely to occur periodically, and could result in material changes to the amount of revenue recognized each year in the future.&amp;#160;&amp;#160;In addition, estimated performance periods may change if development program
s encounter delays, or the Company and its collaborators decide to expand or contract the clinical plans for a drug candidate in various disease indications.&amp;#160;&amp;#160;Also, if a collaborator terminates an agreement in accordance with the terms of the agreement, the Company would recognize any unamortized remainder of an up-front or previously deferred payment at the time of the termination.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;b. &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"&gt;&amp;#174; &lt;/font&gt;Technology Licensing&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;d
iv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company enters into non-exclusive license agreements with third parties that allow the third party to utilize the Company&amp;#8217;s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology in its internal research programs.&amp;#160;&amp;#160;The terms of these agreements include up-front payments and entitle the Company to receive royalties on any future sales of products discovered by the third party using the Company&amp;#8217;s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"&gt;&amp;#174;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;&amp
;#160;&lt;/font&gt;technology.&amp;#160;&amp;#160;Up-front payments under these agreements, where continuing involvement is required of the Company, are deferred and recognized ratably over their respective license periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;c. Product Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;&amp;#160;Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss has pa
ssed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, and the Company has no further performance obligations.&amp;#160;&amp;#160;Revenue and deferred revenue from product sales are recorded net of applicable provisions for prompt pay discounts, product returns, estimated rebates payable under governmental programs (including Medicaid), distribution fees, and other sales-related deductions.&amp;#160;&amp;#160;The Company reviews its estimates of rebates payable each period and records any necessary adjustments in the current period&amp;#8217;s net product sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Investment Income&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block;
 TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Interest income, which is included in investment income, is recognized as earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Research and development expenses include costs directly
 attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to the Company&amp;#8217;s clinical trials, clinical trial expenses, the full cost of manufacturing drug for use in research, preclinical development, and clinical trials, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services.&amp;#160;&amp;#160;All costs associated with research and development are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: b
lock; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors.&amp;#160;&amp;#160;The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as contract research organizations (&amp;#8220;CROs&amp;#8221;), independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies.&amp;#160;&amp;#160;For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter the trial, and/or the period over which clinical investigators or contract research organizations are expected to provide
 services.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Clinical activities which relate principally to clinical sites and other administrative functions to manage the Company&amp;#8217;s clinical trials are performed primarily by CROs.&amp;#160;&amp;#160;CROs typically perform most of the start-up activities for the Company&amp;#8217;s trials, including document preparation, site identification, screening and preparation, pre-study visits, training, and program management.&amp;#160;&amp;#160;On a budgeted basis, these start-up costs are typically&amp;#160;10% to&amp;#160;20% of the total contract value.&amp;#160;&amp;#160;On an actual basis, this percentage range can be significantly wider, as many of the Company&amp;#8217;s contracts are either expanded or reduced in
 scope compared to the original budget, while start-up costs for the particular trial may not change materially.&amp;#160;&amp;#160;These start-up costs usually occur within a few months after the contract has been executed and are event driven in nature. The remaining activities and related costs, such as patient monitoring and administration, generally occur ratably throughout the life of the individual contract or study. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial and/or penalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For clinical study sites, where payments are made perio
dically on a per-patient basis to the institutions performing the clinical study, the Company accrues expense on an estimated cost-per-patient basis, based on subject enrollment and activity in each quarter.&amp;#160;&amp;#160;The amount of clinical study expense recognized in a quarter may vary from period to period based on the duration and progress of the study, the activities to be performed by the sites each quarter, the required level of patient enrollment, the rate at which patients actually enroll in and drop-out of the clinical study, and the number of sites involved in the study.&amp;#160;&amp;#160;Clinical trials that bear the greatest risk of change in estimates are typically those that have a significant number of sites, require a large number of patients, have complex patient screening requirements, and span multiple years.&amp;#160;&amp;#160;During the course of a trial, the Company adjusts its rate of clinical expense recognition if actual results differ from the Company&amp;#8217;s estimates
.&amp;#160;&amp;#160;The Company&amp;#8217;s estimates and assumptions for clinical expense recognition could differ significantly from its actual results, which could cause material increases or decreases in research and development expenses in future periods when the actual results become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company recognizes stock-based compensation expense for grants of stock option 
awards and restricted stock under the Company&amp;#8217;s Long-Term Incentive Plans, to employees and non-employee members of the Company&amp;#8217;s board of directors, based on the grant-date fair value of those awards.&amp;#160;&amp;#160;The grant-date fair value of an award is generally recognized as compensation expense over the award&amp;#8217;s requisite service period.&amp;#160;&amp;#160;In addition, the Company has granted performance-based stock option awards which vest based upon the optionee satisfying certain performance and service conditions as defined in the agreements.&amp;#160;&amp;#160;Potential compensation cost, measured on the grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options will vest, which is based on whether the Company consider the options&amp;#8217; performance conditions to be probable of attainment.&amp;#160;&amp;#160;The Company&amp;#8217;s estimates of the number of performance-based options that wil
l vest will be revised, if necessary, in subsequent periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards.&amp;#160;&amp;#160;Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of our Common Stock price, (ii) the periods of time over which employees and members of the board of directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates.&amp;#160;&amp;#160;Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited.&amp;#16
0;&amp;#160;This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.&amp;#160;&amp;#160;Under this method, deferred tax liabilities and assets are determined on
 the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&amp;#8220;temporary differences&amp;#8221;) at enacted tax rates in effect for the years in which the differences are expected to reverse.&amp;#160;&amp;#160;A valuation allowance is established for deferred tax assets for which realization is uncertain.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Uncertain tax positions are accounted for in accordance with FASB authoritative guidance, which prescribes a comprehensive model for the manner in which a company should recognize, measure, present, and disclose in its financial statements all material uncertain tax positions that the company has taken or expects to take on a tax return.&amp;#160;&a
mp;#160;Those positions, for which management's assessment is that there is more than a 50% probability of sustaining the position upon challenge by a taxing authority based upon its technical merits, are subjected to certain measurement criteria.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company&amp;#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /
&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Comprehensive income (loss) of the Company includes net income (loss) adjusted for the change in net unrealized gain or loss on marketable securities, net of any tax effect.&amp;#160;&amp;#160;Comprehensive income (loss) for the years ended December 31, 2010, 2009, and 2008 have been included in the Statements of Stockholders&amp;#8217; Equity.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="
DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents, marketable securities (see Note 6), and receivables from sanofi-aventis.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Per Share Data&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; F
ONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Net income (loss) per share, basic and diluted, is computed on the basis of the net income (loss) for the period divided by the weighted average number of shares of Common Stock and Class A Stock outstanding during the period.&amp;#160;&amp;#160;Basic net income (loss) per share excludes restricted stock awards until vested.&amp;#160;&amp;#160;Diluted net income per share is based upon the weighted average number of shares of Common Stock and Class A Stock outstanding, and of common stock equivalents outstanding when dilutive.&amp;#160;&amp;#160;Common stock equivalents include: (i) outstanding stock options and restricted stock awards under the Company&amp;#8217;s Long-Term Incentive Plans, which are included under the &amp;#8220;treasury stock method&amp;#8221; when dilutive, and (ii) Common Stock to be issued under the assumed conversion of the Company&amp;#8217;s formerly outstanding convertible senior subordinated notes, 
which are included under the &amp;#8220;if-converted method&amp;#8221; when dilutive.&amp;#160;&amp;#160;The computation of diluted net loss per share for the years ended December 31, 2010, 2009, and 2008 does not include common stock equivalents, since such inclusion would be antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Risks and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Developing and commercializing new medicines entails significant risk and expense.&amp;#160
;&amp;#160;Since its inception, the Company has not generated any significant sales or profits from the commercialization of ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"&gt;&amp;#210;&lt;/font&gt; or any of the Company&amp;#8217;s other product candidates.&amp;#160;&amp;#160;Before revenues from the commercialization of the Company&amp;#8217;s current or future product candidates can be realized, the Company (or its collaborators) must overcome a number of hurdles which include successfully completing research and development and obtaining regulatory approval from the FDA and regulatory authorities in other countries.&amp;#160;&amp;#160;In addition, the biotechnology and pharmaceutical industries are rapidly evolving and highly competitive, and new developments may render the Company&amp;#8217;s products and technologies uncompetitive or obsolete.&amp;#160;&amp;#160;The Company may be subject to legal claims by third parties seeking to enforce
 patents to limit or prohibit the Company from marketing or selling its products.&amp;#160;&amp;#160;The Company is also dependent upon the services of its employees, consultants, collaborators, and certain third-party suppliers, including single-source unaffiliated third-party suppliers of certain raw materials and equipment. Regeneron, as licensee, licenses certain technologies that are important to the Company&amp;#8217;s business which impose various obligations on the Company.&amp;#160;&amp;#160;If Regeneron fails to comply with these requirements, licensors may have the right to terminate the Company&amp;#8217;s licenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company has generally incurred net losses and negative cash flows from operations since its in
ception.&amp;#160;&amp;#160;Revenues to date have principally been limited to (i) up-front, license, milestone, and reimbursement payments from the Company&amp;#8217;s collaborators and other entities related to the Company&amp;#8217;s development activities and technology platforms, (ii) payments for past contract manufacturing activities, (iii) ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; product sales, and (iv) investment income.&amp;#160;&amp;#160;Collaboration revenue in 2010 was earned from sanofi-aventis and Bayer HealthCare under collaboration agreements (see Note 3 for the terms of these agreements).&amp;#160;&amp;#160;These collaboration agreements contain early termination provisions that are exercisable by sanofi-aventis or Bayer HealthCare, as applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT
: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.&amp;#160;&amp;#160;Actual results could differ from those estimates.&amp;#160;&amp;#160;Estimates which could have a significant impact on the Company&amp;#8217;s financial statements include:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" 
cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Product rebates and returns in connection with the recognition of revenue from product sales.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" alig
n="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements to develop and commercialize product candidates and utilize the Company&amp;#8217;s technology platforms.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Periods over which certain clinical trial costs, including costs for clini
cal activities performed by contract research organizations, are recognized as research and development expenses.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In connection with stock option awards, (i) the fair value of stock options on their date of grant using the Black-Scholes option-pricing model, based on assumptions with respect to (a) expected volatility of the Company&amp;#8217;s Common Stock price, (b) the periods of time for which employees and members of the Company&amp;#8217;s board
 of directors are expected to hold their options prior to exercise (expected lives), (c) expected dividend yield on the Company&amp;#8217;s Common Stock, and (d) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options&amp;#8217; expected lives; (ii) the number of stock option awards that are expected to be forfeited; and (iii) with respect to performance-based stock option awards, if and when the options&amp;#8217; performance conditions are considered to be probable of attainment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0p
t" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company&amp;#8217;s determination of whether marketable securities are other than temporarily impaired.&amp;#160;&amp;#160;The Company conducts a quarterly review of its portfolio of marketable securities, using both quantitative and qualitative factors, to determine, for securities whose current fair value is less than their cost, whether the decline in fair value below cost is other-than-temporary.&amp;#160;&amp;#160;In making this determination, the Company considers factors such as the length of time and the extent to which fair value has been less than cost, financial condition and near-term prospects of the issuer, recommendations of investment advisors, and forecasts of economic, market, or industry trends.&amp;#160;&amp;#160;This review process also includes an evaluation of the Company&amp;#8217;s ability and intent to hold individual securities until they mature or their full value can be re
covered.&amp;#160;&amp;#160;This review is subjective and requires a high degree of judgment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Useful lives of property, plant, and equipment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, ser
if"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Capitalized inventory costs associated with the Company&amp;#8217;s products prior to regulatory approval when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 27pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPL
AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The extent to which deferred tax assets and liabilities are offset by a valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In addition, the Company&amp;#8217;s share of VEGF Trap-Eye development expenses incurred by Bayer HealthCare, including the Company&amp;#8217;s share of Bayer HealthCare&amp;#8217;s estimated VEGF Trap-Eye development expenses for the most recent fiscal quarter, are included in research and development expenses.&amp;#160;&amp;#160;The Bayer HealthCare estimate for the most recent fiscal quarter is adjusted in the subsequent quarter to reflect actual expenses for the quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: bl
ock; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Future Impact of Recently Issued Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In October 2009, the FASB amended its authoritative guidance on multiple-deliverable revenue arrangements.&amp;#160;&amp;#160;The amended guidance provides greater ability to separate and allocate consideration to be received in a multiple-element revenue arrangement by requiring the use of estimated selling prices to allocate the consideration, thereby eliminating the use of the residual method of a
llocation.&amp;#160;&amp;#160;The amended guidance also requires expanded qualitative and quantitative disclosures surrounding multiple-deliverable revenue arrangements.&amp;#160;&amp;#160;This guidance may be applied retrospectively or prospectively for new or materially modified arrangements.&amp;#160;&amp;#160;The Company will adopt this amended guidance effective for the fiscal year beginning January 1, 2011.&amp;#160;&amp;#160;Management does not anticipate that the adoption of this guidance will have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In March 2010, the FASB amended its authoritative guidance on the milestone method of revenue recognition.&amp;#160;&amp;#160;The milestone method of reven
ue recognition has now been codified as an acceptable revenue recognition model when a milestone is deemed to be substantive.&amp;#160;&amp;#160;This guidance may be applied retrospectively to all arrangements or prospectively for milestones achieved after the adoption of the guidance.&amp;#160;&amp;#160;The Company will adopt this amended guidance for the fiscal year beginning January 1, 2011.&amp;#160;&amp;#160;Management does not anticipate that the adoption of this guidance will have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c00041">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c00041">0000872589</dei:EntityCentralIndexKey>
  <!--Net cash provided by (used in) financing activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="u000" decimals="-3" contextRef="c00041">243306000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net cash provided by (used in) financing activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="u000" decimals="-3" contextRef="c00007">31363000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net cash provided by (used in) financing activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="u000" decimals="-3" contextRef="c00000">-192858000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net proceeds from the issuance of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="u000" decimals="-3" contextRef="c00041">196790000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Net proceeds from the issuance of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="u000" decimals="-3" contextRef="c00007">8598000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Net proceeds from the issuance of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="u000" decimals="-3" contextRef="c00000">7949000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Purchases of marketable securities-->
  <us-gaap:PaymentsToAcquireMarketableSecurities unitRef="u000" decimals="-3" contextRef="c00041">605124000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <!--Purchases of marketable securities-->
  <us-gaap:PaymentsToAcquireMarketableSecurities unitRef="u000" decimals="-3" contextRef="c00007">199997000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <!--Purchases of marketable securities-->
  <us-gaap:PaymentsToAcquireMarketableSecurities unitRef="u000" decimals="-3" contextRef="c00000">581139000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <!--Decrease (Increase) in prepaid expenses and other assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="u000" decimals="-3" contextRef="c00041">-2723000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Decrease (Increase) in prepaid expenses and other assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="u000" decimals="-3" contextRef="c00007">4574000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Decrease (Increase) in prepaid expenses and other assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="u000" decimals="-3" contextRef="c00000">6560000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Preferred stock, shares authorized-->
  <us-gaap:PreferredStockSharesAuthorized unitRef="u001" decimals="0" contextRef="c00034">30000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized-->
  <us-gaap:PreferredStockSharesAuthorized unitRef="u001" decimals="0" contextRef="c00021">30000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c00041">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c00041">REGENERON PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00001">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00008">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00042">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00002">7948000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00009">9269000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00043">21462000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00000">7949000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00007">9270000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity + Issuance of Common Stock in connection with exercise of stock options, net of shares tendered - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="u000" decimals="-3" contextRef="c00041">21464000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Loss from operations-->
  <us-gaap:OperatingIncomeLoss unitRef="u000" decimals="-3" contextRef="c00041">-97472000</us-gaap:OperatingIncomeLoss>
  <!--Loss from operations-->
  <us-gaap:OperatingIncomeLoss unitRef="u000" decimals="-3" contextRef="c00007">-74103000</us-gaap:OperatingIncomeLoss>
  <!--Loss from operations-->
  <us-gaap:OperatingIncomeLoss unitRef="u000" decimals="-3" contextRef="c00000">-86249000</us-gaap:OperatingIncomeLoss>
  <!--Sanofi-aventis collaboration revenue-->
  <regn:SanofiAventisCollaborationRevenue unitRef="u000" decimals="-3" contextRef="c00041">311332000</regn:SanofiAventisCollaborationRevenue>
  <!--Sanofi-aventis collaboration revenue-->
  <regn:SanofiAventisCollaborationRevenue unitRef="u000" decimals="-3" contextRef="c00007">247140000</regn:SanofiAventisCollaborationRevenue>
  <!--Sanofi-aventis collaboration revenue-->
  <regn:SanofiAventisCollaborationRevenue unitRef="u000" decimals="-3" contextRef="c00000">153972000</regn:SanofiAventisCollaborationRevenue>
  <!--Total stockholders' equity + Balance, December 31, 2007 - Total Stockholders' Equity + Balance, December 31, 2008 - Total Stockholders' Equity-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00034">527815000</us-gaap:StockholdersEquity>
  <!--Total stockholders' equity + Balance, December 31, 2007 - Total Stockholders' Equity + Balance, December 31, 2008 - Total Stockholders' Equity-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00021">396762000</us-gaap:StockholdersEquity>
  <!--Total stockholders' equity + Balance, December 31, 2007 - Total Stockholders' Equity + Balance, December 31, 2008 - Total Stockholders' Equity-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00028">459348000</us-gaap:StockholdersEquity>
  <!--Total stockholders' equity + Balance, December 31, 2007 - Total Stockholders' Equity + Balance, December 31, 2008 - Total Stockholders' Equity-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00014">421514000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2008 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2009 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2010 - Class A Stock Amount- Class A [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00029">2000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2008 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2009 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2010 - Class A Stock Amount- Class A [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00015">2000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2008 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2009 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2010 - Class A Stock Amount- Class A [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00022">2000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2008 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2009 - Class A Stock Amount- Class A [Member] + Balance, December 31, 2010 - Class A Stock Amount- Class A [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00035">2000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2008 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00030">77000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2008 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00016">78000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2008 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00023">79000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2008 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Amount- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Amount- Common Stock [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00036">87000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2008 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2009 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2010 - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00031">1253235000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2008 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2009 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2010 - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00017">1294813000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2008 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2009 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2010 - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00024">1336732000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2008 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2009 - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Balance, December 31, 2010 - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00037">1575780000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2010 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00032">-794136000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2010 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00018">-873265000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2010 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00025">-941095000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Balance, December 31, 2010 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00038">-1045563000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2008 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2009 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2010 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00033">170000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2008 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2009 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2010 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00019">-114000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2008 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2009 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2010 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00026">1044000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2007 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2008 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2009 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member] + Balance, December 31, 2010 - Accumulated Other Comprehensive Income (Loss)- Accumulated Other Comprehensive Income (Loss) [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00039">-2491000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2010 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00020">-79413000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2010 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00027">-66672000</us-gaap:StockholdersEquity>
  <!--Balance, December 31, 2008 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Balance, December 31, 2010 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity unitRef="u000" decimals="-3" contextRef="c00040">-108003000</us-gaap:StockholdersEquity>
  <!--Total liabilities-->
  <us-gaap:Liabilities unitRef="u000" decimals="-3" contextRef="c00034">561617000</us-gaap:Liabilities>
  <!--Total liabilities-->
  <us-gaap:Liabilities unitRef="u000" decimals="-3" contextRef="c00021">344440000</us-gaap:Liabilities>
  <!--Deferred revenue - other, current portion-->
  <us-gaap:DeferredRevenueCurrent unitRef="u000" decimals="-3" contextRef="c00034">35217000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue - other, current portion-->
  <us-gaap:DeferredRevenueCurrent unitRef="u000" decimals="-3" contextRef="c00021">27021000</us-gaap:DeferredRevenueCurrent>
  <!--Commitments and Contingencies-->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;11.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;a. Leases&lt;/font&gt;&lt;/div&
gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Descriptions of Lease Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company leases laboratory and office facilities in Tarrytown, New York, under a December 2006 lease agreement, as amended (the &amp;#8220;Tarrytown Lease&amp;#8221;).&amp;#160;&amp;#160;The facilities leased by the Company under the Tarrytown Lease include (i) space in previously existing buildings, (ii) newly constructed space in two new buildings (&amp;#8220;Buildings A and B&amp;#8221;) that was complet
ed during the third quarter of 2009 and, (iii) under a December 2009 amendment to the Tarrytown Lease, additional new space that is under construction in a third new building (&amp;#8220;Building C&amp;#8221;) and expected to be completed in the first quarter of 2011.&amp;#160;&amp;#160;The Tarrytown Lease will expire in June 2024 and contains three renewal options to extend the term of the lease by five years each, escalations at 2.5% per annum, and early termination options for various portions of the space exclusive of the newly constructed space in Buildings A and B.&amp;#160;&amp;#160;&amp;#160;The Tarrytown Lease provides for monthly payments over its term and additional charges for utilities, taxes, and operating expenses.&amp;#160;&amp;#160;Certain premises under the Tarrytown Lease are accounted for as operating leases.&amp;#160;&amp;#160;However, for Buildings A, B, and C that the Company is leasing, the Company is deemed, in substance, to be the owner of the landlord&amp;#8217;s buildings in accor
dance with the application of FASB authoritative guidance, and the landlord&amp;#8217;s costs of constructing these new facilities are required to be capitalized on the Company&amp;#8217;s books as a non-cash transaction, offset by a corresponding lease obligation on the Company&amp;#8217;s balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In connection with the Tarrytown Lease, at lease inception, the Company issued a&lt;a id="exp1" name="exp1"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt; letter of credit in the amount of $1.6 million to its landlord, which was collateralized by a $1.6 million bank certificate of deposit at December 31, 2009.&lt;a id="exp3" name="exp3"&gt;&lt;!--EFPlaceholder--&gt;&lt;/a&gt;&amp;#160;&amp;#160;During 2010, the Company increased t
his letter of credit to $3.4 million, in accordance with the provisions of the Tarrytown Lease, and collateralized the letter of credit with cash and marketable debt securities totaling $3.6 million.&amp;#160;&amp;#160;Such collateral at December 31, 2010 and 2009 has been classified as restricted cash and marketable securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;In October 2008, the Company entered into a sublease with sanofi-aventis U.S. Inc. for office space in Bridgewater, New Jersey.&amp;#160;&amp;#160;The lease commenced in January 2009 and expires in July 2011. The Company also formerly leased additional office space in Tarrytown, New York under operating subleases that ended at various times through September 2009.&lt;/font&gt;&lt;
/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company also leases certain laboratory and office equipment under operating and capital leases which expire at various times through 2013.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Commitments under Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;
div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The estimated future minimum noncancelable lease commitments under operating leases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&l
t;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Facilities&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&a
mp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#
160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$6,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; F
ONT-FAMILY: times new roman"&gt;$225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$6,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;5,468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; T
EXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;5,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;6,617&lt;/font&gt;&lt;/div&gt;&lt;/td
&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;6,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DI
SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;6,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;6,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FO
NT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;6,866&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;6,866&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;fon
t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;64,196&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;64,196&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/t
d&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$95,978&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$367&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;fon
t style="DISPLAY: inline"&gt;$96,345&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Rent expense under operating leases was:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;Year Ending December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 
black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Facilities&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#
160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline"&gt;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;
font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$7,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&
gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;7,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;8
,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;6,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;416&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.
5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;6,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In addition to its rent expense for various facilities, the Company paid rental charges for utilities, real estate taxes, and operating expenses of $10.3 million, $8.4 million, and $8.4 million for the years ended December 31, 2010, 2009, and 2008, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Com
mitments under Capital Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In 2010, the Company entered into capital leases in connection with acquisitions of new equipment.&amp;#160;&amp;#160;The lease obligations are collateralized with marketable debt securities totaling $3.5 million; such collateral has been classified as restricted cash and marketable securities at December 31, 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPL
AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The estimated future minimum noncancelable lease commitments under capital leases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: 
inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Equipment&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR
GIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$1,137&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;1,135&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;
/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;995&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Total minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;3,267&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left"
 width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Less: amount representing interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;(438)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font styl
e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;$2,829&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;At the end of the lease term, the Company is required to purchase the leased equipment for a nominal amount defined in the lease agreement.&amp;#160;&amp;#160;At December 31, 2010, capital lease obligations totaling $2.8 million were included in other liabilities.&amp;#160;&amp;#160;There were no capital lease obligations at December 31, 2009.&amp;#160;&amp;#160;As of December 31, 2010, the Company had $0.7 million of financing available under a capital equipment lease line.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;
br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Facility Lease Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;As described above, in connection with the application of FASB authoritative guidance to the Company&amp;#8217;s lease of office and laboratory facilities in Buildings A and B, the Company capitalized the landlord&amp;#8217;s costs of constructing the new facilities, which totaled $58.4 million as of December 31, 2010, and recognized a corresponding facility lease obligation of $58.4 million.&amp;#160;&amp;#160;The Company also recognized, as additional facility lease oblig
ation, reimbursements totaling $56.9 million from the Company&amp;#8217;s landlord during 2010 and 2009 for tenant improvement costs that the Company incurred since, under FASB authoritative guidance, such payments that the Company receives from its landlord are deemed to be a financing obligation.&amp;#160;&amp;#160;&amp;#160;Monthly lease payments on these facilities are allocated between the land element of the lease (which is accounted for as an operating lease) and the facility lease obligation, based on the estimated relative fair values of the land and buildings.&amp;#160;&amp;#160;The imputed interest rate applicable to the facility lease obligation is approximately 11%.&amp;#160;&amp;#160;The new facilities were placed in service by the Company in September 2009.&amp;#160;&amp;#160;For the years ended December 31, 2010 and 2009, the Company recognized in its statement of operations $9.1 million and $2.3 million, respectively, of interest expense in connection with the facility lease obligation.&amp;
#160;&amp;#160;At December 31, 2010 and 2009, the facility lease obligation balance in connection with Buildings A and B was $113.7 million and $81.0 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In addition, as described above, in December 2009, the Company amended its December 2006 agreement to lease additional new laboratory and office facilities in Building C that is under construction.&amp;#160;&amp;#160;In connection with the application of FASB authoritative guidance to the Company&amp;#8217;s lease of these additional new facilities, the Company is deemed, in substance, to be the owner of the landlord&amp;#8217;s building, and the landlord&amp;#8217;s costs of constructing Building C is required to be capitalized on the Company&amp;#8217;s
 books as a non-cash transaction, offset by a corresponding lease obligation on the Company&amp;#8217;s balance sheet.&amp;#160;&amp;#160;As of December 31, 2010, the Company capitalized $27.8 million of the landlord&amp;#8217;s costs of constructing Building C, and recognized a corresponding facility lease obligation of $27.8 million.&amp;#160;&amp;#160;The Company also recognized, as additional facility lease obligation, reimbursements totaling $14.2 million from the Company&amp;#8217;s landlord during 2010 for tenant improvement costs that the Company incurred since, under FASB authoritative guidance, such payments that the Company receives from its landlord are deemed to be a financing obligation.&amp;#160;&amp;#160;&amp;#160;Monthly lease payments on these facilities will commence in January 2011.&amp;#160;&amp;#160;Rent expense in connection with the land element of these additional facilities, which is accounted for as an operating lease, commenced in December 2009 and is recorded as a deferred liabil
ity until lease payments commence in January 2011.&amp;#160;&amp;#160;In addition, interest expense is imputed at a rate of approximately 9%, and is capitalized and deferred in connection with this facility lease obligation.&amp;#160;&amp;#160;At December 31, 2010 and 2009, the facility lease obligation balance in connection with Building C was $46.4 million and $28.0 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The estimated future minimum noncancelable commitments under these facility lease obligations, as of December 31, 2010, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOT
TOM: black 2px solid" valign="top" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Buildings A and B&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="
center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Building C&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" alig
n="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$11,347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$2,468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA
MILY: Times New Roman"&gt;$13,815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;12,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2,767&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE
XT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;15,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;12,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4,285&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;17,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;13,090&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&l
t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;17,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;13,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&
gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4,524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;17,867&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="29%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font styl
e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;124,515&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;43,783&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;168,298&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times
 New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;$187,741&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;$62,230&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT
- -SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;$249,971&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;b. Research Collaboration and Licensing Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreemen
ts with related and unrelated companies, scientific collaborators, universities, and consultants.&amp;#160;&amp;#160;These agreements contain varying terms and provisions which include fees and milestones to be paid by the Company, services to be provided, and ownership rights to certain proprietary technology developed under the agreements.&amp;#160;&amp;#160;Some of the agreements contain provisions which require the Company to pay royalties, as defined, at rates that range from 0.25% to 16.5%, in the event the Company sells or licenses any proprietary products developed under the respective agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Certain agreements under which the Company is required to pay fees permit the Company, upon 30 to 90-day written notice, 
to terminate such agreements.&amp;#160;&amp;#160;With respect to payments associated with these agreements, the Company incurred expenses of $1.6 million, $2.8 million, and $3.5 million for the years ended December 31, 2010, 2009, and 2008, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In connection with the Company&amp;#8217;s receipt of marketing approval from the FDA for ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"&gt;&amp;#210;&lt;/font&gt; for the treatment of CAPS, in 2008, the Company commenced paying royalties under various licensing agreements based on ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; net product sales.&amp
;#160;&amp;#160;For the years ended December 31, 2010, 2009, and 2008, ARCALYST&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; royalties totaled $1.7 million, $1.5 million, and $0.6 million, respectively, and are included in cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In July 2008, the Company and Cellectis S.A. (&amp;#8220;Cellectis&amp;#8221;) entered into an Amended and Restated Non-Exclusive License Agreement (the &amp;#8220;Cellectis Agreement&amp;#8221;).&amp;#160;&amp;#160;The Cellectis Agreement resolved a dispute between the part
ies related to the interpretation of a license agreement entered into by the parties in December 2003 pursuant to which the Company licensed certain patents and patent applications from Cellectis.&amp;#160;&amp;#160;Pursuant to the Cellectis Agreement, in July 2008, the Company made a non-refundable $12.5 million payment to Cellectis (the &amp;#8220;Cellectis Payment&amp;#8221;) and agreed to pay Cellectis a low single-digit royalty based on revenue received by the Company from any future licenses or sales of the Company&amp;#8217;s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; or &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; products and services.&amp;#160;&amp;#160;No royalties are payable to Cellectis with respect to the Company&amp;#8217;
s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; license agreements with AstraZeneca and Astellas or the Company&amp;#8217;s antibody collaboration with sanofi-aventis.&amp;#160;&amp;#160;Moreover, no royalties are payable to Cellectis on any revenue from commercial sales of antibodies from the Company&amp;#8217;s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#174;&lt;/font&gt; technology.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company began amortizing the Cellectis Payment in the second quarter of 2008 in propo
rtion to past and future anticipated revenues under the Company&amp;#8217;s license agreements with AstraZeneca and Astellas and the Discovery and Preclinical Development Agreement under the Company&amp;#8217;s antibody collaboration with sanofi-aventis (as amended in November 2009).&amp;#160;&amp;#160;In 2010, 2009, and 2008, the Company recognized $0.9 million, $2.3 million, and $2.7 million, respectively, of expense in connection with the Cellectis Payment.&amp;#160;&amp;#160;At December 31, 2010 and 2009, the unamortized balance of the Cellectis Payment, which was included in other assets, was $6.6 million and $7.6 million, respectively.&amp;#160;&amp;#160;The Company estimates that it will recognize expense of $1.0 million in each of 2011, 2012, and 2013, and $0.9 million in each of 2014 and 2015, in connection with the Cellectis Payment.&lt;/font&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!--Cash paid for income taxes-->
  <us-gaap:IncomeTaxesPaid unitRef="u000" decimals="-3" contextRef="c00041">0</us-gaap:IncomeTaxesPaid>
  <!--Cash paid for income taxes-->
  <us-gaap:IncomeTaxesPaid unitRef="u000" decimals="-3" contextRef="c00007">0</us-gaap:IncomeTaxesPaid>
  <!--Cash paid for income taxes-->
  <us-gaap:IncomeTaxesPaid unitRef="u000" decimals="-3" contextRef="c00000">3079000</us-gaap:IncomeTaxesPaid>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaid unitRef="u000" decimals="-3" contextRef="c00041">12737000</us-gaap:InterestPaid>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaid unitRef="u000" decimals="-3" contextRef="c00007">2525000</us-gaap:InterestPaid>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaid unitRef="u000" decimals="-3" contextRef="c00000">9348000</us-gaap:InterestPaid>
  <!--Payments in connection with capital lease obligation-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations unitRef="u000" decimals="-3" contextRef="c00041">104000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Payments in connection with capital lease obligation-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations unitRef="u000" decimals="-3" contextRef="c00007">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Payments in connection with capital lease obligation-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations unitRef="u000" decimals="-3" contextRef="c00000">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense unitRef="u000" decimals="-3" contextRef="c00041">489252000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense unitRef="u000" decimals="-3" contextRef="c00007">398762000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense unitRef="u000" decimals="-3" contextRef="c00000">274903000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Class A Stock, shares outstanding- Class A [Member]-->
  <us-gaap:CommonStockSharesOutstanding unitRef="u001" decimals="0" contextRef="c00035">2182036</us-gaap:CommonStockSharesOutstanding>
  <!--Class A Stock, shares outstanding- Class A [Member]-->
  <us-gaap:CommonStockSharesOutstanding unitRef="u001" decimals="0" contextRef="c00022">2244698</us-gaap:CommonStockSharesOutstanding>
  <!--Common Stock, shares outstanding-->
  <us-gaap:CommonStockSharesOutstanding unitRef="u001" decimals="0" contextRef="c00034">87238301</us-gaap:CommonStockSharesOutstanding>
  <!--Common Stock, shares outstanding-->
  <us-gaap:CommonStockSharesOutstanding unitRef="u001" decimals="0" contextRef="c00021">78860862</us-gaap:CommonStockSharesOutstanding>
  <!--Accounts payable and accrued expenses-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="u000" decimals="-3" contextRef="c00034">53658000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Accounts payable and accrued expenses-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="u000" decimals="-3" contextRef="c00021">49031000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Repurchases or repayment of notes payable-->
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable unitRef="u000" decimals="-3" contextRef="c00041">0</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <!--Repurchases or repayment of notes payable-->
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable unitRef="u000" decimals="-3" contextRef="c00007">0</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <!--Repurchases or repayment of notes payable-->
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable unitRef="u000" decimals="-3" contextRef="c00000">-200807000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <!--Net cash provided by (used in) operating activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="u000" decimals="-3" contextRef="c00041">96344000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net cash provided by (used in) operating activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="u000" decimals="-3" contextRef="c00007">-72230000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net cash provided by (used in) operating activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="u000" decimals="-3" contextRef="c00000">-89086000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Other long term liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent unitRef="u000" decimals="-3" contextRef="c00034">7350000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other long term liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent unitRef="u000" decimals="-3" contextRef="c00021">3959000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="u000" decimals="-3" contextRef="c00002">1107000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="u000" decimals="-3" contextRef="c00009">1391000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="u000" decimals="-3" contextRef="c00043">2867000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="u000" decimals="-3" contextRef="c00000">1107000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="u000" decimals="-3" contextRef="c00007">1391000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Total Stockholders' Equity-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="u000" decimals="-3" contextRef="c00041">2867000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Purchases of restricted marketable securities-->
  <us-gaap:PaymentsToAcquireRestrictedInvestments unitRef="u000" decimals="-3" contextRef="c00041">7063000</us-gaap:PaymentsToAcquireRestrictedInvestments>
  <!--Purchases of restricted marketable securities-->
  <us-gaap:PaymentsToAcquireRestrictedInvestments unitRef="u000" decimals="-3" contextRef="c00007">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
  <!--Purchases of restricted marketable securities-->
  <us-gaap:PaymentsToAcquireRestrictedInvestments unitRef="u000" decimals="-3" contextRef="c00000">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
  <!--Total current assets-->
  <us-gaap:AssetsCurrent unitRef="u000" decimals="-3" contextRef="c00034">357622000</us-gaap:AssetsCurrent>
  <!--Total current assets-->
  <us-gaap:AssetsCurrent unitRef="u000" decimals="-3" contextRef="c00021">425508000</us-gaap:AssetsCurrent>
  <!--Accounts receivable - other-->
  <us-gaap:AccountsReceivableNetCurrent unitRef="u000" decimals="-3" contextRef="c00034">13509000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts receivable - other-->
  <us-gaap:AccountsReceivableNetCurrent unitRef="u000" decimals="-3" contextRef="c00021">2865000</us-gaap:AccountsReceivableNetCurrent>
  <!--Statement of Cash Flows-->
  <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;19.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Statement of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Supplemental disclosure of noncash investing and financing activities:&lt;/font&g
t;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Included in accounts payable and accrued expenses at December 31, 2010, 2009, and 2008 were $10.7 million, $9.8 million, and $7.0 million of accrued capital expenditures, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Included in accounts payable and accrued expenses at December 31, 2009, 2008, and 2007 were $2.6 million, $1.5 million, and $1.1 million, respectively, of accrued 401(k) Savings Plan contribution expense.&amp;#160;&amp;#160;During the first quarter of 2010, 2009, and 20
08, the Company contributed 111,419, 81,086, and 58,575 shares, respectively, of Common Stock to the 401(k) Savings Plan in satisfaction of these obligations.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Pursuant to the application of FASB authoritative guidance to the Company&amp;#8217;s lease of office and laboratory facilities in Tarrytown, New York (see Note 11a), the Company recognized a facility lease obligation of $0.2 million and $31.7 million during 2010 and 2009, respectively, in connection with capitalizing, on the Company&amp;#8217;s books, the landlord&amp;#8217;s costs of constructing new facilities that the Company has leased.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block
; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Included in facility lease obligations and property, plant, and equipment at December 31, 2010 was $3.7 million of capitalized and deferred interest for the year ended December 31, 2010, as the related facilities being leased by the Company are currently under construction and lease payments on these facilities do not commence until January 2011.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company incurred capital lease obligations of $2.9 million during 2010 in connection with acquisitions of new equipment.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Included in other assets at December 31, 2010 and 2009 was $0.2 million and $0.7 million, respectively, due to the Company in connection with employee exercises of stock options in December 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Included in marketable securities at December 31, 2010, 2009, and 2008 were $1.4 million, $0.6 million, and $1.7 million of accrued interest income, respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
  <!--Net Loss Per Share Data-->
  <us-gaap:EarningsPerShareTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;18.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Net Loss Per Share Data&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company&amp;#8217;s basic net loss per share amounts have been computed by dividing net loss
 by the weighted average number of Common and Class A shares outstanding.&amp;#160;&amp;#160;Net loss per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights.&amp;#160;&amp;#160;In 2010, 2009, and 2008, the Company reported net losses; therefore, no common stock equivalents were included in the computation of diluted net loss per share since such inclusion would have been antidilutive.&amp;#160;&amp;#160;The calculations of basic and diluted net loss per share are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="37%" colspan="3"&gt;&lt;div style="DISPLAY: b
lock; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY:
 inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2008&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="37%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0
pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;Net loss (Numerator)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$(104,468)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$(67,830)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Ro
man"&gt;$(79,129)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="37%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted-average shares, in thousands (Denominator
)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;82,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;79,782&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt;
 FONT-FAMILY: Times New Roman"&gt;78,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="37%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&
gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$(1.26)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$(0.85)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$(1.00)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT
- -INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Shares issuable upon the exercise of options and vesting of restricted stock awards, which have been excluded from the diluted per share amounts because their effect would have been antidilutive, include the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR
GIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#1
60;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align=
"center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2008&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;21,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: 
Times New Roman"&gt;20,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;17,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$18.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div sty
le="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$17.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$17.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font
 style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Restricted Stock:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="37%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"
&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;Weighted average number, in thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&l
t;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="u001" decimals="-3" contextRef="c00001">59000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="u001" decimals="-3" contextRef="c00008">81000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member] + Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="u001" decimals="-3" contextRef="c00042">111000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Proceeds in connection with facility lease obligations-->
  <regn:ProceedsFromFacilityLeaseObligation unitRef="u000" decimals="-3" contextRef="c00041">47544000</regn:ProceedsFromFacilityLeaseObligation>
  <!--Proceeds in connection with facility lease obligations-->
  <regn:ProceedsFromFacilityLeaseObligation unitRef="u000" decimals="-3" contextRef="c00007">23640000</regn:ProceedsFromFacilityLeaseObligation>
  <!--Proceeds in connection with facility lease obligations-->
  <regn:ProceedsFromFacilityLeaseObligation unitRef="u000" decimals="-3" contextRef="c00000">0</regn:ProceedsFromFacilityLeaseObligation>
  <!--Increase in accounts receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="u000" decimals="-3" contextRef="c00041">27544000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase in accounts receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="u000" decimals="-3" contextRef="c00007">30356000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase in accounts receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="u000" decimals="-3" contextRef="c00000">16892000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Net realized (gain) loss on marketable securities-->
  <us-gaap:GainLossOnInvestments unitRef="u000" decimals="-3" contextRef="c00041">-293000</us-gaap:GainLossOnInvestments>
  <!--Net realized (gain) loss on marketable securities-->
  <us-gaap:GainLossOnInvestments unitRef="u000" decimals="-3" contextRef="c00007">56000</us-gaap:GainLossOnInvestments>
  <!--Net realized (gain) loss on marketable securities-->
  <us-gaap:GainLossOnInvestments unitRef="u000" decimals="-3" contextRef="c00000">-1310000</us-gaap:GainLossOnInvestments>
  <!--Non-cash compensation expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="u000" decimals="-3" contextRef="c00041">39897000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash compensation expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="u000" decimals="-3" contextRef="c00007">31259000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Non-cash compensation expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="u000" decimals="-3" contextRef="c00000">32523000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="u000" decimals="-3" contextRef="c00002">32523000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="u000" decimals="-3" contextRef="c00009">31259000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member] + Stock-based compensation expense - Additional Paid-in Capital- Additional Paid-in Capital [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="u000" decimals="-3" contextRef="c00043">39897000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Total other income (expense)-->
  <us-gaap:NonoperatingIncomeExpense unitRef="u000" decimals="-3" contextRef="c00041">-6996000</us-gaap:NonoperatingIncomeExpense>
  <!--Total other income (expense)-->
  <us-gaap:NonoperatingIncomeExpense unitRef="u000" decimals="-3" contextRef="c00007">2151000</us-gaap:NonoperatingIncomeExpense>
  <!--Total other income (expense)-->
  <us-gaap:NonoperatingIncomeExpense unitRef="u000" decimals="-3" contextRef="c00000">9471000</us-gaap:NonoperatingIncomeExpense>
  <!--Preferred stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none-->
  <us-gaap:PreferredStockValue unitRef="u000" decimals="-3" contextRef="c00034">2000</us-gaap:PreferredStockValue>
  <!--Preferred stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none-->
  <us-gaap:PreferredStockValue unitRef="u000" decimals="-3" contextRef="c00021">2000</us-gaap:PreferredStockValue>
  <!--Marketable securities-->
  <us-gaap:MarketableSecuritiesCurrent unitRef="u000" decimals="-3" contextRef="c00034">136796000</us-gaap:MarketableSecuritiesCurrent>
  <!--Marketable securities-->
  <us-gaap:MarketableSecuritiesCurrent unitRef="u000" decimals="-3" contextRef="c00021">134255000</us-gaap:MarketableSecuritiesCurrent>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c00041">2010-12-31</dei:DocumentPeriodEndDate>
  <!--Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="u001" decimals="-3" contextRef="c00003">-11000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="u001" decimals="-3" contextRef="c00010">-4000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member] + Conversion of Class A Stock to Common Stock - Class A Stock Shares- Class A [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="u001" decimals="-3" contextRef="c00044">-63000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="u001" decimals="-3" contextRef="c00001">11000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="u001" decimals="-3" contextRef="c00008">4000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member] + Conversion of Class A Stock to Common Stock - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="u001" decimals="-3" contextRef="c00042">63000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Net cash (used in) provided by investing activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="u000" decimals="-3" contextRef="c00041">-434153000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net cash (used in) provided by investing activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="u000" decimals="-3" contextRef="c00007">146000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net cash (used in) provided by investing activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="u000" decimals="-3" contextRef="c00000">30815000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Decrease (increase) in restricted cash-->
  <us-gaap:IncreaseDecreaseInRestrictedCash unitRef="u000" decimals="-3" contextRef="c00041">-1122000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <!--Decrease (increase) in restricted cash-->
  <us-gaap:IncreaseDecreaseInRestrictedCash unitRef="u000" decimals="-3" contextRef="c00007">-50000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <!--Decrease (increase) in restricted cash-->
  <us-gaap:IncreaseDecreaseInRestrictedCash unitRef="u000" decimals="-3" contextRef="c00000">50000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <!--Selling, general, and administrative-->
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="u000" decimals="-3" contextRef="c00041">65201000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, general, and administrative-->
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="u000" decimals="-3" contextRef="c00007">52923000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, general, and administrative-->
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="u000" decimals="-3" contextRef="c00000">48880000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Total revenues-->
  <us-gaap:Revenues unitRef="u000" decimals="-3" contextRef="c00041">459074000</us-gaap:Revenues>
  <!--Total revenues-->
  <us-gaap:Revenues unitRef="u000" decimals="-3" contextRef="c00007">379268000</us-gaap:Revenues>
  <!--Total revenues-->
  <us-gaap:Revenues unitRef="u000" decimals="-3" contextRef="c00000">238457000</us-gaap:Revenues>
  <!--Contract research and other-->
  <us-gaap:ContractsRevenue unitRef="u000" decimals="-3" contextRef="c00041">6945000</us-gaap:ContractsRevenue>
  <!--Contract research and other-->
  <us-gaap:ContractsRevenue unitRef="u000" decimals="-3" contextRef="c00007">6434000</us-gaap:ContractsRevenue>
  <!--Contract research and other-->
  <us-gaap:ContractsRevenue unitRef="u000" decimals="-3" contextRef="c00000">7070000</us-gaap:ContractsRevenue>
  <!--Other collaboration revenue-->
  <regn:OtherCollaborationRevenue unitRef="u000" decimals="-3" contextRef="c00041">75393000</regn:OtherCollaborationRevenue>
  <!--Other collaboration revenue-->
  <regn:OtherCollaborationRevenue unitRef="u000" decimals="-3" contextRef="c00007">67317000</regn:OtherCollaborationRevenue>
  <!--Other collaboration revenue-->
  <regn:OtherCollaborationRevenue unitRef="u000" decimals="-3" contextRef="c00000">31166000</regn:OtherCollaborationRevenue>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital unitRef="u000" decimals="-3" contextRef="c00034">1575780000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital unitRef="u000" decimals="-3" contextRef="c00021">1336732000</us-gaap:AdditionalPaidInCapital>
  <!--Common Stock A- Class A [Member]-->
  <us-gaap:CommonStockValue unitRef="u000" decimals="-3" contextRef="c00035">2000</us-gaap:CommonStockValue>
  <!--Common Stock A- Class A [Member]-->
  <us-gaap:CommonStockValue unitRef="u000" decimals="-3" contextRef="c00022">2000</us-gaap:CommonStockValue>
  <!--Common Stock-->
  <us-gaap:CommonStockValue unitRef="u000" decimals="-3" contextRef="c00034">87000</us-gaap:CommonStockValue>
  <!--Common Stock-->
  <us-gaap:CommonStockValue unitRef="u000" decimals="-3" contextRef="c00021">79000</us-gaap:CommonStockValue>
  <!--Restricted cash and marketable securities-->
  <us-gaap:RestrictedCashAndInvestmentsNoncurrent unitRef="u000" decimals="-3" contextRef="c00034">7518000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
  <!--Restricted cash and marketable securities-->
  <us-gaap:RestrictedCashAndInvestmentsNoncurrent unitRef="u000" decimals="-3" contextRef="c00021">1600000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
  <!--Long-Term Incentive Plans-->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;13.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Long-Term Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;During 2000, the Company established the Regeneron Pharm
aceuticals, Inc. 2000 Long-Term Incentive Plan which, as amended and restated (the &amp;#8220;2000 Incentive Plan&amp;#8221;), provides for the issuance of up to 29,307,016 shares of Common Stock in respect of awards.&amp;#160;&amp;#160;Employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company&amp;#8217;s board of directors, (collectively, &amp;#8220;Participants&amp;#8221;) may receive awards as determined by a committee of independent directors (&amp;#8220;Committee&amp;#8221;).&amp;#160;&amp;#160;The awards that may be made under the 2000 Incentive Plan include: (a) Incentive Stock Options (&amp;#8220;ISOs&amp;#8221;) and Nonqualified Stock Options, (b) shares of Restricted Stock, (c) shares of Phantom Stock, (d) Stock Bonuses, and (e) Other Awards.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align=
"justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Stock Option awards grant Participants the right to purchase shares of Common Stock at prices determined by the Committee; however, in the case of an ISO, the option exercise price will not be less than the fair market value of a share of Common Stock on the date the Option is granted.&amp;#160;&amp;#160;Options vest over a period of time determined by the Committee, generally on a pro rata basis over a three to five year period.&amp;#160;&amp;#160;The Committee also determines the expiration date of each Option; however, no ISO is exercisable more than ten years after the date of grant.&amp;#160;&amp;#160;The maximum term of options that have been awarded under the 2000 Incentive Plan is ten years.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font sty
le="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Restricted Stock awards grant Participants shares of restricted Common Stock or allow Participants to purchase such shares at a price determined by the Committee.&amp;#160;&amp;#160;Such shares are nontransferable for a period determined by the Committee (&amp;#8220;vesting period&amp;#8221;).&amp;#160;&amp;#160;Should employment terminate, as defined by the 2000 Incentive Plan, the ownership of the Restricted Stock, which has not vested, will be transferred to the Company, except under defined circumstances with Committee approval, in consideration of amounts, if any, paid by the Participant to acquire such shares.&amp;#160;&amp;#160;In addition, if the Company requires a return of the Restricted Shares, it also has the right to require a return of all dividends paid on such shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-IND
ENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Phantom Stock awards provide the Participant the right to receive, within 30 days of the date on which the share vests, an amount, in cash and/or shares of the Company&amp;#8217;s Common Stock as determined by the Committee, equal to the sum of the fair market value of a share of Common Stock on the date such share of Phantom Stock vests and the aggregate amount of cash dividends paid with respect to a share of Common Stock during the period from the grant date of the share of Phantom Stock to the date on which the share vests.&amp;#160;&amp;#160;Stock Bonus awards are bonuses payable in shares of Common Stock which are granted at the discretion of the Committee.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font styl
e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Other Awards are other forms of awards which are valued based on the Company&amp;#8217;s Common Stock.&amp;#160;&amp;#160;Subject to the provisions of the 2000 Incentive Plan, the terms and provisions of such Other Awards are determined solely on the authority of the Committee.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The 2000 Incentive Plan contains provisions that allow for the Committee to provide for the immediate vesting of awards upon a change in control of the Company, as defined in the plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justif
y"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;As of December 31, 2010, there were 434,564 shares available for future grants under the 2000 Incentive Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;During 1990, the Company established the 1990 Incentive Plan which, as amended, provided for a maximum of 6,900,000 shares of Common Stock in respect of awards.&amp;#160;&amp;#160;Employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company&amp;#8217;s board of directors, received awards as determined by a committee of independent directors.&amp;#160;&amp;#160;Under the provisions of the 1990 Incentive Plan, there will be no future awards from the plan.&amp;#160;&amp
;#160;Awards under the 1990 Incentive Plan consisted of Incentive Stock Options and Nonqualified Stock Options which generally vested on a pro rata basis over a three or five year period and had a term of ten years.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 4.5pt"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="WIDTH: 18pt"&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;a.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Stock Options&lt;/font&gt;&lt;/di
v&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Transactions involving stock option awards during 2010 under the 1990 and 2000 Incentive Plans are summarized in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="36%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: bl
ock; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;Stock Options:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIG
HT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div s
tyle="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;Exercise Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt
; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Weighted-Average Remaining Contractual Term (in &lt;font style="DISPLAY: inline"&gt;years)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARG
IN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Intrinsic Value (in &lt;font style="DISPLAY: inline"&gt;thousands)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="36%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Outstanding at December 31, 2009&lt;/
font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;21,788,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$18.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Ti
mes New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="36%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2010:&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;G
ranted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4,319,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$29.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="36%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT
: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;(183,252)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$20.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt
;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="36%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;(887,281)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="ri
ght"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$38.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="36%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; 
MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;(1,675,830)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$15.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="36%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT
- -SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Outstanding at December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;23,362,248&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$19.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI
GHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;6.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$308,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times Ne
w Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="36%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Vested and expected to vest at December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;22,803,097&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 1
0pt; FONT-FAMILY: Times New Roman"&gt;$19.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;6.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$304,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="36%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="13%"&gt;&lt;font style="DIS
PLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="36%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Exercisable at December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;12,910,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valig
n="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$17.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$201,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT
: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;The Company satisfies stock option exercises with newly issued shares of the Company&amp;#8217;s Common Stock.&amp;#160;&amp;#160;The total intrinsic value of stock options exercised during 2010, 2009, and 2008 was $21.4 million, $13.2 million, and $11.9 million,&amp;#160;&amp;#160;&amp;#160;&amp;#160;respectively.&amp;#160;&amp;#160;The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inli
ne; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company grants stock options with exercise prices that are equal to or greater than the average market price of the Company&amp;#8217;s Common Stock on the date of grant (&amp;#8220;Market Price&amp;#8221;).&amp;#160;&amp;#160;The table below summarizes the weighted-average exercise prices and weighted-average grant-date fair values of options issued during the years ended December 31, 2010, 2009, and 2008.&amp;#160;&amp;#160;The fair value of each option granted under the 2000 Incentive Plan during 2010, 2009, and 2008 was estimated on the date of grant using the Black-Scholes option-pricing model.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTO
M: black 2px solid" valign="top" width="15%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Options Granted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Weighted-Average Exercise &lt;font style="DISPLAY: inline"&gt;Pr
ice&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Weighted-Average Fair &lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2010:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt
;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4,319,856&lt;/
font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$29.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$13.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times N
ew Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2009:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt
;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;3,490,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$20.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DI
SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$10.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2008:&lt;/font&gt;&l
t;/div&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;Exercise price equal to Market Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE
: 10pt; FONT-FAMILY: Times New Roman"&gt;4,126,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$17.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="11%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$8.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="32%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="
DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For the years ended December 31, 2010, 2009, and 2008, $29.4 million, $27.4 million, and $30.3 million, respectively, of non-cash stock-based compensation expense related to non-performance based stock option awards was recognized in operating expenses.&amp;#160;&amp;#160;As of December 31, 2010, there was $57.5 million of stock-based compensation cost related to outstanding non-performance based stock options, net of estimated forfeitures, which had not yet bee
n recognized in operating expenses.&amp;#160;&amp;#160;The Company expects to recognize this compensation cost over a weighted-average period of 1.8 years.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In addition, there were 2,486,510 performance-based options which were unvested as of December 31, 2010 of which, subject to the optionee satisfying certain service conditions, 664,760 options that were issued in 2005 would vest upon achieving certain defined sales targets for the Company&amp;#8217;s products and 1,821,750 options that were issued in 2008, 2009, and 2010 would vest upon achieving certain development milestones for the Company&amp;#8217;s product candidates.&amp;#160;&amp;#160;In light of the status of the Company&amp;#8217;s development programs at Decemb
er 31, 2010, the Company estimates that all of the performance-based options issued in 2008, 2009, and 2010 will vest since the Company considers these options&amp;#8217; performance conditions to be probable of attainment.&amp;#160;&amp;#160;Principally as a result, in 2010, the Company recognized $8.1 million of non-cash stock-based compensation expense related to these performance options.&amp;#160;&amp;#160;In light of the status of the Company&amp;#8217;s development programs at December 31, 2009, the Company estimated that approximately two-thirds of the performance-based options issued in 2008 and 2009 would vest; therefore, in 2009, the Company recognized $1.7 million of non-cash stock-based compensation expense, related to these performance-based options.&amp;#160;&amp;#160;As of December 31, 2010, there was $17.6 million of stock-based compensation cost which had not yet been recognized in operating expenses related to the performance-based options that the Company currently estimates will vest.&am
p;#160;&amp;#160;&amp;#160;The Company expects to recognize this compensation cost over a weighted-average period of 2 years.&amp;#160;&amp;#160;In addition, potential compensation cost of $2.5 million related to the performance options issued in 2005, whose performance conditions (based on current facts and circumstances) are not currently considered by the Company to be probable of attainment, will begin to be recognized only if, and when, the Company estimates that it is probable that these options will vest.&amp;#160;&amp;#160;The Company&amp;#8217;s estimates of the number of performance-based options that will vest will be revised, if necessary, in subsequent periods.&amp;#160;&amp;#160;Changes in these estimates may materially affect the amount of stock-based compensation recognized in future periods related to performance-based options.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;
 MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Fair value Assumptions:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2010, 2009, and 2008.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="t
op" width="26%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 27p
t; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#1
60;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2008&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;47%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top
" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;54%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;53%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="26%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Expected lives from grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;fon
t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;5.6 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;5.9 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;5.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td val
ign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="26%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SI
ZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2.11%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;2.87%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="15%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;1.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 
0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Expected volatility has been estimated based on actual movements in the Company&amp;#8217;s stock price over the most recent historical periods equivalent to the options&amp;#8217; expected lives.&amp;#160;&amp;#160;Expected lives are principally based on the Company&amp;#8217;s historical exercise experience with previously issued employee and board of directors option grants.&amp;#160;&amp;#160;The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.&amp;#160;&amp;#160;The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the options&amp;#8217; expected lives.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br
 /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 4.5pt"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="WIDTH: 18pt"&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;b.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Restricted Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL
Y: Times New Roman"&gt;A summary of the Company&amp;#8217;s activity related to Restricted Stock awards for the year ended December 31, 2010 is summarized below:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="41%"&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;Restricted Stock:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"&gt;&lt;div style="DISPLAY
: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Number of &lt;font style="DISPLAY: inline"&gt;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DIS
PLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Grant Date Fair &lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="41%"&gt;&lt;div style="DISPLAY: block; MARGI
N-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Outstanding at December 31, 2009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$21.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="41%"&gt;&lt;font style="DISPLAY: inline; FON
T-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="41%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2010:&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%
"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;345,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$30.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="41%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;
&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Outstanding at December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;845,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="14%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$25.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT
- -INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company recognized non-cash stock-based employee compensation expense from Restricted Stock awards of $2.4 million, $2.2 million, and $2.2 million in 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;As of December 31, 2010, there were 845,000 unvested shares of Restricted Stock outstanding and $14.6 million of stock-based compensation cost related to these unvested shares which had not yet been recognized in operating expenses.&amp;#160;&amp;#160;The Company expects to recognize this compensation cost over a weighted-average period of 2.4 years.&lt;/font&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!--Issuance of restricted Common Stock under Long-Term Incentive Plan - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross unitRef="u001" decimals="-3" contextRef="c00042">345000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <!--Balance, December 31, 2007 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2008 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2009 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2010 - Class A Stock Shares- Class A [Member]-->
  <us-gaap:SharesIssued unitRef="u001" decimals="-3" contextRef="c00029">2260000</us-gaap:SharesIssued>
  <!--Balance, December 31, 2007 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2008 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2009 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2010 - Class A Stock Shares- Class A [Member]-->
  <us-gaap:SharesIssued unitRef="u001" decimals="-3" contextRef="c00015">2249000</us-gaap:SharesIssued>
  <!--Balance, December 31, 2007 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2008 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2009 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2010 - Class A Stock Shares- Class A [Member]-->
  <us-gaap:SharesIssued unitRef="u001" decimals="-3" contextRef="c00022">2245000</us-gaap:SharesIssued>
  <!--Balance, December 31, 2007 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2008 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2009 - Class A Stock Shares- Class A [Member] + Balance, December 31, 2010 - Class A Stock Shares- Class A [Member]-->
  <us-gaap:SharesIssued unitRef="u001" decimals="-3" contextRef="c00035">2182000</us-gaap:SharesIssued>
  <!--Balance, December 31, 2007 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2008 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesIssued unitRef="u001" decimals="-3" contextRef="c00030">76592000</us-gaap:SharesIssued>
  <!--Balance, December 31, 2007 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2008 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesIssued unitRef="u001" decimals="-3" contextRef="c00016">77642000</us-gaap:SharesIssued>
  <!--Balance, December 31, 2007 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2008 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesIssued unitRef="u001" decimals="-3" contextRef="c00023">78861000</us-gaap:SharesIssued>
  <!--Balance, December 31, 2007 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2008 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2009 - Common Stock Shares- Common Stock [Member] + Balance, December 31, 2010 - Common Stock Shares- Common Stock [Member]-->
  <us-gaap:SharesIssued unitRef="u001" decimals="-3" contextRef="c00036">87238000</us-gaap:SharesIssued>
  <!--Payments in connection with facility lease obligations-->
  <regn:PaymentsInConnectionWithFacilityLeaseObligation unitRef="u000" decimals="-3" contextRef="c00041">-924000</regn:PaymentsInConnectionWithFacilityLeaseObligation>
  <!--Payments in connection with facility lease obligations-->
  <regn:PaymentsInConnectionWithFacilityLeaseObligation unitRef="u000" decimals="-3" contextRef="c00007">-875000</regn:PaymentsInConnectionWithFacilityLeaseObligation>
  <!--Payments in connection with facility lease obligations-->
  <regn:PaymentsInConnectionWithFacilityLeaseObligation unitRef="u000" decimals="-3" contextRef="c00000">0</regn:PaymentsInConnectionWithFacilityLeaseObligation>
  <!--Investment income-->
  <us-gaap:InvestmentIncomeNonoperating unitRef="u000" decimals="-3" contextRef="c00041">2122000</us-gaap:InvestmentIncomeNonoperating>
  <!--Investment income-->
  <us-gaap:InvestmentIncomeNonoperating unitRef="u000" decimals="-3" contextRef="c00007">4488000</us-gaap:InvestmentIncomeNonoperating>
  <!--Investment income-->
  <us-gaap:InvestmentIncomeNonoperating unitRef="u000" decimals="-3" contextRef="c00000">18161000</us-gaap:InvestmentIncomeNonoperating>
  <!--Net product sales-->
  <us-gaap:SalesRevenueGoodsNet unitRef="u000" decimals="-3" contextRef="c00041">25254000</us-gaap:SalesRevenueGoodsNet>
  <!--Net product sales-->
  <us-gaap:SalesRevenueGoodsNet unitRef="u000" decimals="-3" contextRef="c00007">18364000</us-gaap:SalesRevenueGoodsNet>
  <!--Net product sales-->
  <us-gaap:SalesRevenueGoodsNet unitRef="u000" decimals="-3" contextRef="c00000">6249000</us-gaap:SalesRevenueGoodsNet>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent unitRef="u000" decimals="-3" contextRef="c00034">6789000</us-gaap:OtherAssetsNoncurrent>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent unitRef="u000" decimals="-3" contextRef="c00021">7338000</us-gaap:OtherAssetsNoncurrent>
  <!--Income Taxes-->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;16.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For the year ended December 31, 2010, the Company incurred a net loss for tax purposes and recognized a 
full valuation allowance against deferred taxes.&amp;#160;&amp;#160;Accordingly, no provision or benefit for income taxes was recorded in 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For the year ended December 31, 2009, the Company incurred a net loss for tax purposes and recognized a full valuation allowance against deferred taxes.&amp;#160;&amp;#160;In 2009, the Company recognized a $4.1 million income tax benefit, consisting of (i) $2.7 million resulting from a provision in the Worker, Homeownership, and Business Assistance Act of 2009 that allows the Company to claim a refund of U.S. federal alternative minimum tax (&amp;#8220;AMT&amp;#8221;) that the Company paid in connection with its 2007 U.S. federal income tax return, as described below, (ii) $0.7 milli
on income tax benefit resulting from a provision in the American Recovery and Reinvestment Act of 2009 that allows the Company to claim a refund for a portion of its unused pre-2006 research tax credits on its 2009 U.S. federal income tax return, and (iii) $0.7 million income tax benefit in connection with the net tax effect of the Company&amp;#8217;s unrealized gain on &amp;#8220;available-for-sale&amp;#8221; marketable securities, which is included in other comprehensive income in 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For the year ended December 31, 2008, the Company incurred a net loss for tax purposes and recognized a full valuation allowance against deferred taxes.&amp;#160;&amp;#160;During 2008, the Company implemented a tax planning strategy to util
ize net operating loss carry-forwards (which were otherwise due to expire in 2008 through 2012) on its 2007 U.S. federal and New York State income tax returns that were filed in September 2008.&amp;#160;&amp;#160;The tax planning strategy included electing, for tax purposes only, to capitalize $142.1 million of 2007 research and development (&amp;#8220;R&amp;amp;D&amp;#8221;) costs and amortize these costs over ten years for tax purposes.&amp;#160;&amp;#160;By capitalizing these R&amp;amp;D costs, the Company was able to generate taxable income for tax year 2007 and utilize the net operating loss carry-forwards to offset this taxable income.&amp;#160;&amp;#160;As a result, the Company incurred and paid income tax expense of $3.1 million in 2008, which related to U.S. federal and New York State AMT and included $0.2 million of interest and penalties.&amp;#160;&amp;#160;This expense was partly offset by the Company&amp;#8217;s recognition of a $0.7 million income tax benefit in 2008, resulting from a provision
 in the Housing Assistance Tax Act of 2008 that allowed the Company to claim a refund for a portion of its unused pre-2006 research tax credits on its 2008 U.S federal income tax return.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The tax effect of temporary differences, net operating loss carry-forwards, and research and experimental and other tax credit carry-forwards as of December 31, 2010 and 2009 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;
/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160
;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL
Y: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" 
align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Net operating loss carry-forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;243,893&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim
es new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;200,266&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Fixed assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne
w roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;13,600&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;
font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;13,833&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&
gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;70,443&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;73,865&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/
font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;39,120&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&am
p;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;29,736&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Research and e
xperimental and other tax credit carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;45,588&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: le
ft" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;22,377&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Capitalized research and development costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/t
d&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;38,865&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 1
0pt; FONT-FAMILY: times new roman"&gt;49,107&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt;
 FONT-FAMILY: times new roman"&gt;10,863&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;10,142&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style
="PADDING-BOTTOM: 2px" valign="bottom" width="76%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(462,372&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" v
align="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;(399,326&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&l
t;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;--&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt
; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;--&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-IND
ENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company&amp;#8217;s valuation allowance increased by $63.0 million in 2010, due primarily to increases in the net operating loss carry-forward and tax credit carry-forwards.&amp;#160;&amp;#160;In 2009, the Company&amp;#8217;s valuation allowance increased by $19.0 million, due primarily to the increase in the net operating loss carry-forward.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company is primarily subject to U.S. federal and New York State income tax. The difference between the Company&amp;#8217;s effective income tax rate and th
e U.S federal statutory rate of 35% is primarily attributable to an increase in the deferred tax valuation allowance.&amp;#160;&amp;#160;Due to the Company&amp;#8217;s history of losses, all tax years remain open to examination by U.S. federal and state tax authorities.&amp;#160;&amp;#160;In January 2011, U.S. federal tax authorities commenced an examination of the Company&amp;#8217;s 2007 and 2008 U.S. federal income tax returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;As of December 31, 2010 and 2009, the Company had no accruals for interest or penalties related to income tax matters.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT
: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;As of December 31, 2010, the Company had available for tax purposes unused net operating loss carry-forwards of $614.9 million which will expire in various years from 2018 to 2030 and included $7.1 million of net operating loss carry-forwards related to exercises of Nonqualified Stock Options and disqualifying dispositions of Incentive Stock Options, the tax benefit from which, if realized, will be credited to additional paid-in capital. The Company's research and experimental and other tax credit carry-forwards expire in various years from 2011 to 2030.&amp;#160;&amp;#160;Under the Internal Revenue Code and similar state provisions, substantial changes in the Company&amp;#8217;s ownership have resulted in an annual limitation on the amount of net operating loss and tax credit carry-forwards that can be utilized in future years to offset future taxable income.&amp;#160;&amp;#160;This annual limitation
 may result in the expiration of net operating losses and tax credit carry-forwards before utilization.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The following table summarizes the gross amounts of unrecognized tax benefits at the beginning and end of 2010:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&g
t;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: -36pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" align="left" width="88%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Balance as of January 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" width="1%"&gt;&lt;font style="DIS
PLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" align="left" width="88%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Gross increases related to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" align="right" wid
th="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,550&lt;/font&gt;&lt;/td&gt;&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="88%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Gross increases related to prior year tax positions&lt;/fo
nt&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;9,269&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="88%"&gt;&lt;div style="
DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Balance as of December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;12,819&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"&gt;&lt;font style="DISPLAY: inline; 
FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In 2010, the gross increases in unrecognized tax benefits related to prior year tax positions was primarily due to the Company&amp;#8217;s calculations of certain pre-2010 tax credits.&amp;#160;&amp;#160;Due to the amounts of the Company&amp;#8217;s net operating loss carry-forward and tax credit carry-forwards, the Company has not accrued interest or penalties related to these unrecognized tax benefits.&amp;#160;&amp;#160;In addition, unrecognized tax benefits at December 31, 2010, if recognized, would not affect the Company&amp;#8217;s effective tax rate since the adjustments to deferred tax assets would be fully offset by adju
stments to the Company&amp;#8217;s valuation allowance.&amp;#160;&amp;#160;For the years ended December 31, 2009 and 2008, income tax positions that were deemed uncertain under the recognition thresholds and measurement attributes prescribed in FASB authoritative guidance were not significant.&lt;/font&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <!--Employee Savings Plan-->
  <regn:Employeesavingsplantextblock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;15.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Employee Savings Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In 1993, the Company adopted the provisions of the Regeneron Pharmaceuticals, Inc. 401(k) Savings 
Plan (the &amp;#8220;Savings Plan&amp;#8221;).&amp;#160;&amp;#160;The terms of the Savings Plan provide for employees who have met defined service requirements to participate in the Savings Plan by electing to contribute to the Savings Plan a percentage of their compensation to be set aside to pay their future retirement benefits, as defined.&amp;#160;&amp;#160;The Savings Plan, as amended and restated, provides for the Company to make discretionary contributions (&amp;#8220;Contribution&amp;#8221;), as defined.&amp;#160;&amp;#160;The Company recognized $3.2 million, $2.6 million, and $1.5 million of Contribution expense in 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;At December 31, 2010 and 2009, accrued Contribution expense totaled $2.9 million and $2.6 million, respectively.&amp;#160;&amp;#160;During the first quarter of 2011 and 2010, the Company contributed 91,761 and 111,419 shares, respectively, of Common Stock to the Savings Plan in satisfaction of these obligations.&lt;/font&gt;&lt;/div&g
t;</regn:Employeesavingsplantextblock>
  <!--Executive Stock Purchase Plan-->
  <regn:ExecutivestockpurchasePlantextblock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;14.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Executive Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In 1989, the Company adopted an Executive Stock Purchase Plan (the &amp;#8220;Plan&
amp;#8221;) under which 1,027,500 shares of Class A Stock were reserved for restricted stock awards.&amp;#160;&amp;#160;The Plan provides for the compensation committee of the board of directors to award employees, directors, consultants, and other individuals (&amp;#8220;Plan participants&amp;#8221;) who render service to the Company the right to purchase Class A Stock at a price set by the compensation committee.&amp;#160;&amp;#160;The Plan provides for the vesting of shares as determined by the compensation committee and, should the Company's relationship with a Plan participant terminate before all shares are vested, unvested shares will be repurchased by the Company at a price per share equal to the original amount paid by the Plan participant.&amp;#160;&amp;#160;During 1989 and 1990, a total of 983,254 shares were issued, all of which vested as of December 31, 1999.&amp;#160;&amp;#160;As of December 31, 2010, there were 44,246 shares available for future grants under the Plan.&lt;/font&gt;&lt;/div&gt;<
/regn:ExecutivestockpurchasePlantextblock>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c00041">2010</dei:DocumentFiscalYearFocus>
  <!--Increase (Decrease) in accounts payable, accrued expenses, and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="u000" decimals="-3" contextRef="c00041">7605000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase (Decrease) in accounts payable, accrued expenses, and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="u000" decimals="-3" contextRef="c00007">12577000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase (Decrease) in accounts payable, accrued expenses, and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="u000" decimals="-3" contextRef="c00000">-5729000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Weighted average shares outstanding, basic and diluted-->
  <regn:WeightedAverageSharesOutstandingBasicAndDiluted unitRef="u001" decimals="-3" contextRef="c00041">82926000</regn:WeightedAverageSharesOutstandingBasicAndDiluted>
  <!--Weighted average shares outstanding, basic and diluted-->
  <regn:WeightedAverageSharesOutstandingBasicAndDiluted unitRef="u001" decimals="-3" contextRef="c00007">79782000</regn:WeightedAverageSharesOutstandingBasicAndDiluted>
  <!--Weighted average shares outstanding, basic and diluted-->
  <regn:WeightedAverageSharesOutstandingBasicAndDiluted unitRef="u001" decimals="-3" contextRef="c00000">78827000</regn:WeightedAverageSharesOutstandingBasicAndDiluted>
  <!--Interest expense-->
  <us-gaap:InterestExpense unitRef="u000" decimals="-3" contextRef="c00041">9118000</us-gaap:InterestExpense>
  <!--Interest expense-->
  <us-gaap:InterestExpense unitRef="u000" decimals="-3" contextRef="c00007">2337000</us-gaap:InterestExpense>
  <!--Interest expense-->
  <us-gaap:InterestExpense unitRef="u000" decimals="-3" contextRef="c00000">7752000</us-gaap:InterestExpense>
  <!--Class A Stock, shares authorized- Class A [Member]-->
  <us-gaap:CommonStockSharesAuthorized unitRef="u001" decimals="0" contextRef="c00035">40000000</us-gaap:CommonStockSharesAuthorized>
  <!--Class A Stock, shares authorized- Class A [Member]-->
  <us-gaap:CommonStockSharesAuthorized unitRef="u001" decimals="0" contextRef="c00022">40000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common Stock, shares authorized-->
  <us-gaap:CommonStockSharesAuthorized unitRef="u001" decimals="0" contextRef="c00034">160000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common Stock, shares authorized-->
  <us-gaap:CommonStockSharesAuthorized unitRef="u001" decimals="0" contextRef="c00021">160000000</us-gaap:CommonStockSharesAuthorized>
  <!--Class A Stock, par value- Class A [Member]-->
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="u000" decimals="3" contextRef="c00035">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Class A Stock, par value- Class A [Member]-->
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="u000" decimals="3" contextRef="c00022">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common Stock, par value-->
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="u000" decimals="3" contextRef="c00034">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common Stock, par value-->
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="u000" decimals="3" contextRef="c00021">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="u000" decimals="-3" contextRef="c00034">-1045563000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="u000" decimals="-3" contextRef="c00021">-941095000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Facility lease obligations-->
  <regn:FacilityLeaseObligationNoncurrent unitRef="u000" decimals="-3" contextRef="c00034">159355000</regn:FacilityLeaseObligationNoncurrent>
  <!--Facility lease obligations-->
  <regn:FacilityLeaseObligationNoncurrent unitRef="u000" decimals="-3" contextRef="c00021">109022000</regn:FacilityLeaseObligationNoncurrent>
  <!--Stockholders Equity-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;12.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Stockholders Equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company's Restated Certificate of Incorporation provides for the issuance of up 
to 40 million shares of Class A Stock, par value $0.001 per share, and 160 million shares of Common Stock, par value $0.001 per share.&amp;#160;&amp;#160;Shares of Class A Stock are convertible, at any time, at the option of the holder into shares of Common Stock on a share-for-share basis.&amp;#160;&amp;#160;&amp;#160;Holders of Class A Stock have rights and privileges identical to Common Stockholders except that each share of Class A is entitled to ten votes per share, while each share of Common Stock is entitled to one vote per share.&amp;#160;&amp;#160;Class A Stock may only be transferred to specified Permitted Transferees, as defined.&amp;#160;&amp;#160;Under the Company&amp;#8217;s Restated Certificate of Incorporation, the Company&amp;#8217;s board of directors is authorized to issue up to 30 million shares of preferred stock, in series, with rights, privileges, and qualifications of each series determined by the board of directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 
0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In September 2003, sanofi-aventis purchased 2,799,552 newly issued, unregistered shares of the Company&amp;#8217;s Common Stock for $45.0 million.&amp;#160;&amp;#160;See Note 3.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In December 2007, sanofi-aventis purchased 12 million newly issued, unregistered shares of the Company&amp;#8217;s Common Stock for an aggregate cash price of $312.0 million.&amp;#160;&amp;#160;As a condition to the closing of this transaction, sanofi-aventis entered into an investor agreement with the Company, which was amended in N
ovember 2009.&amp;#160;&amp;#160;Under the amended investor agreement, sanofi-aventis has three demand rights to require the Company to use all reasonable efforts to conduct a registered underwritten public offering with respect to shares of the Company&amp;#8217;s Common Stock beneficially owned by sanofi-aventis immediately after the closing of the transaction.&amp;#160;&amp;#160;Until the later of the fifth anniversaries of the expiration or earlier termination of the License and Collaboration Agreement, as amended in 2009, under the Company&amp;#8217;s antibody collaboration with sanofi-aventis (see Note 3) and the Company&amp;#8217;s collaboration agreement with sanofi-aventis for the development and commercialization of aflibercept (see Note 3), sanofi-aventis will be bound by certain &amp;#8220;standstill&amp;#8221; provisions.&amp;#160;&amp;#160;These provisions include an agreement not to acquire more than a specified percentage of the outstanding shares of the Company&amp;#8217;s Class A Stock and 
Common Stock.&amp;#160;&amp;#160;The percentage is currently 25% and will increase to 30% after December 20, 2011.&amp;#160;&amp;#160;Under the amended investor agreement, sanofi-aventis has also agreed not to dispose of any shares of the Company&amp;#8217;s Common Stock that were beneficially owned by sanofi-aventis immediately after the closing of the transaction until December 20, 2017, subject to certain limited exceptions.&amp;#160;&amp;#160;Following December 20, 2017, sanofi-aventis will be permitted to sell shares of the Company&amp;#8217;s Common Stock (i) in a registered underwritten public offering undertaken pursuant to the demand registration rights granted to sanofi-aventis and described above, subject to the underwriter's broad distribution of securities sold, (ii) pursuant to Rule 144 under the Securities Act and transactions exempt from registration under the Securities Act, subject to a volume limitation of one million shares of the Company&amp;#8217;s Common Stock every three months and a 
prohibition on selling to beneficial owners, or persons that would become beneficial owners as a result of such sale, of 5% or more of the outstanding shares of the Company&amp;#8217;s Common Stock, and (iii) into an issuer tender offer, or a tender offer by a third party that is recommended or not opposed by the Company&amp;#8217;s board of directors.&amp;#160;&amp;#160;Sanofi-aventis has agreed to vote, and cause its affiliates to vote, all shares of the Company&amp;#8217;s voting securities they are entitled to vote, at sanofi-aventis' election, either as recommended by the Company&amp;#8217;s board of directors or proportionally with the votes cast by the Company&amp;#8217;s other shareholders, except with respect to certain change of control transactions, liquidation or dissolution, stock issuances equal to or exceeding 10% of the then outstanding shares or voting rights of the Company&amp;#8217;s Class A Stock and Common Stock, and new equity compensation plans or amendments if not materially consisten
t with the Company&amp;#8217;s historical equity compensation practices.&amp;#160;&amp;#160;The rights and restrictions under the investor agreement are subject to termination upon the occurrence of certain events.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In October 2010, the Company completed an underwritten public offering of 6,325,000 shares of Common Stock and received net proceeds of $174.8 million.&amp;#160;&amp;#160;Sanofi-aventis purchased 1,017,401 shares of Common Stock in this offering.&lt;/font&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00041">-104468000</us-gaap:NetIncomeLoss>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00007">-67830000</us-gaap:NetIncomeLoss>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00000">-79129000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2010 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00004">-79129000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2010 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00011">-67830000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2008 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2009 - Accumulated Deficit- Accumulated Deficit [Member] + Net loss, 2010 - Accumulated Deficit- Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00045">-104468000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2008 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2010 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00005">-79129000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2008 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2010 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00012">-67830000</us-gaap:NetIncomeLoss>
  <!--Net loss, 2008 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2009 - Comprehensive Loss- Comprehensive Loss [Member] + Net loss, 2010 - Comprehensive Loss- Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss unitRef="u000" decimals="-3" contextRef="c00046">-104468000</us-gaap:NetIncomeLoss>
  <!--Net loss before income tax expense-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments unitRef="u000" decimals="-3" contextRef="c00041">-104468000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Net loss before income tax expense-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments unitRef="u000" decimals="-3" contextRef="c00007">-71952000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Net loss before income tax expense-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments unitRef="u000" decimals="-3" contextRef="c00000">-76778000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Preferred stock, shares issued-->
  <us-gaap:PreferredStockSharesIssued unitRef="u001" decimals="0" contextRef="c00034">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued-->
  <us-gaap:PreferredStockSharesIssued unitRef="u001" decimals="0" contextRef="c00021">0</us-gaap:PreferredStockSharesIssued>
  <!--Facility lease obligations, current portion-->
  <regn:FacilityLeaseObligationsCurrentPortion unitRef="u000" decimals="-3" contextRef="c00034">675000</regn:FacilityLeaseObligationsCurrentPortion>
  <!--Facility lease obligations, current portion-->
  <regn:FacilityLeaseObligationsCurrentPortion unitRef="u000" decimals="-3" contextRef="c00021">0</regn:FacilityLeaseObligationsCurrentPortion>
  <!--Deferred Revenue-->
  <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;9.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Deferred Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 36pt"&gt;&lt;/font&gt;Deferred revenue as of December 31, 2010 and 200
9 consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt
;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0
pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;Received from sanofi-aventis (see Note 3a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valig
n="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$19,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$17,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Bayer HealthCare (see Note 3b)
&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;9,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;9,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;
Received for technology license agreements (see Note 4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;25,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;11,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F
AMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;325&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;5,558&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="
44%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$54,723&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$44,544&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&
lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Long-term portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY:
 times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;Received from sanofi-aventis (see Note 3a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$97,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" wid
th="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$90,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;Received from Bayer&amp;#160;&amp;#160;HealthCare (see Note 3b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt
;37,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;46,951&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="44%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160;&amp;#160;&amp;#160;Received for technology license agreements (see Note 4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" ali
gn="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;151,708&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="44%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="9%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&
gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$285,856&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;$137,884&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies2009 xsi:nil="true" contextRef="c00041"/>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies2009 xsi:nil="true" contextRef="c00007"/>
  <!--Total assets-->
  <us-gaap:Assets unitRef="u000" decimals="-3" contextRef="c00034">1089432000</us-gaap:Assets>
  <!--Total assets-->
  <us-gaap:Assets unitRef="u000" decimals="-3" contextRef="c00021">741202000</us-gaap:Assets>
  <!--Legal Matters-->
  <us-gaap:LegalCostsPolicyTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;17.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Legal Matters&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;From time to time, the Company is a party to legal proceedings in the course of the Company&amp;#8217;s bu
siness.&amp;#160;&amp;#160;The Company does not expect any such current legal proceedings to have a material adverse effect on the Company&amp;#8217;s business or financial condition.&amp;#160;&amp;#160;Legal costs associated with the Company&amp;#8217;s resolution of legal proceedings are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;On November 19, 2010, the Company filed a complaint against Genentech, Inc. in the United States District Court for the Southern District of New York seeking a declaratory judgment that no activities relating to VEGF Trap infringe any valid claim of certain Genentech patents.&amp;#160;&amp;#160;On January 12, 2011, Genentech filed a motion to dismiss the complaint.&amp;#160;&amp;#160;The motion is currently pending.&a
mp;#160;&amp;#160;The Company may initiate similar actions in countries outside the United States.&lt;/font&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
  <!--Accounts Payable and Accrued Expenses-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;8.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Accounts Payable and Accrued Expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Accounts payable and accrued expenses as of December 31,
 2010 and 2009 consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 201
0&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="46%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Accounts payable&lt
;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$15,589&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;$18,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="46%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Accrued payroll and related costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-IN
DENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;12,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;9,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="46%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Accrued clinical trial expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;9,727&lt;/f
ont&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;11,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="46%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Accrued property, plant, and equipment costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;7,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE
XT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;1,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="46%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Other accrued expenses and liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;6,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt
;6,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="46%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Payable to Bayer HealthCare&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;2,254&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISP
LAY: inline"&gt;1,186&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="46%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;$53,658&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;$49,031&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</
us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <!--Property Plant and Equipment-->
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;7.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Property, Plant, and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 36pt"&gt;&lt;/font&gt;Property, plant, and equ
ipment as of December 31, 2010 and 2009 consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&l
t;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.25pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#160;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="39%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN
- -LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;$2,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160;&amp;#160;&amp;#160;$2,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="39%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Building and improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="
DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;242,035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;177,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="39%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width
="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;4,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="39%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Construction-in-progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;70,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline
; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;58,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="39%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Laboratory and other equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;137,951&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;114,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" alig
n="left" width="39%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Furniture, computer and office equipment, and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;22,235&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;15,964&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;478,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;372,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" width="39%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Less, accumulated de
preciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;(131,307)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;(112,778)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="39%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px dou
ble" valign="top" align="right" width="13%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;$347,450&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline"&gt;$259,676&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Depreciation and am
ortization expense on property, plant, and equipment amounted to $19.7 million, $14.2 million, and $10.6 million for the years ended December 31, 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;Effective in the first quarter of 2010, the estimated useful lives of certain capitalized laboratory and other equipment, which is a component of property, plant, and equipment, were extended.&amp;#160;&amp;#160;The effect of this change in estimate was to lower depreciation expense by $4.0 million and to lower the Company&amp;#8217;s net loss per share by $0.05 for the year ended December 31, 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Included in property, plant, and equipment at December 31, 2010 was $2.8 million of leased equipment under capital leases (see Not
e 11a); related accumulated amortization was $0.1 million at December 31, 2010.&amp;#160;&amp;#160;The Company held no leased equipment under capital leases at December 31, 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Building and improvements at December 31, 2010 and 2009 includes $58.4 million and $58.2 million, respectively, of costs incurred by the Company&amp;#8217;s landlord to construct new laboratory and office facilities in Tarrytown, New York in connection with the Company&amp;#8217;s December 2006 lease, as amended, of these new facilities.&amp;#160;&amp;#160;In addition, construction-in-progress at both December 31, 2010 and 2009 includes $27.8 million of costs incurred by the Company&amp;#8217;s landlord in connection with these new facilities.&amp;#
160;&amp;#160;See Note 11a.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company capitalized interest costs of $6.4 million and $0.5 million in 2010 and 2009, respectively.&amp;#160;&amp;#160;The Company did not capitalize any interest costs in 2008.&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <!--Capital expenditures-->
  <us-gaap:PaymentsToAcquireProductiveAssets unitRef="u000" decimals="-3" contextRef="c00041">99689000</us-gaap:PaymentsToAcquireProductiveAssets>
  <!--Capital expenditures-->
  <us-gaap:PaymentsToAcquireProductiveAssets unitRef="u000" decimals="-3" contextRef="c00007">97318000</us-gaap:PaymentsToAcquireProductiveAssets>
  <!--Capital expenditures-->
  <us-gaap:PaymentsToAcquireProductiveAssets unitRef="u000" decimals="-3" contextRef="c00000">34857000</us-gaap:PaymentsToAcquireProductiveAssets>
  <!--Total adjustments-->
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities unitRef="u000" decimals="-3" contextRef="c00041">200812000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <!--Total adjustments-->
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities unitRef="u000" decimals="-3" contextRef="c00007">-4400000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <!--Total adjustments-->
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities unitRef="u000" decimals="-3" contextRef="c00000">-9957000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <!--Increase (Decrease) in deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="u000" decimals="-3" contextRef="c00041">158151000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="u000" decimals="-3" contextRef="c00007">-27497000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="u000" decimals="-3" contextRef="c00000">-26834000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization unitRef="u000" decimals="-3" contextRef="c00041">19687000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization unitRef="u000" decimals="-3" contextRef="c00007">14247000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization unitRef="u000" decimals="-3" contextRef="c00000">11287000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Loss on early extinguishment of debt-->
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="u000" decimals="-3" contextRef="c00041">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <!--Loss on early extinguishment of debt-->
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="u000" decimals="-3" contextRef="c00007">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <!--Loss on early extinguishment of debt-->
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="u000" decimals="-3" contextRef="c00000">-938000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <!--Total liabilities and stockholders' equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="u000" decimals="-3" contextRef="c00034">1089432000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Total liabilities and stockholders' equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="u000" decimals="-3" contextRef="c00021">741202000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Collaboration and Contract Research Agreements-->
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="c00041">&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 36pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;3.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Collaboration and Contract Research Agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company has entered into va
rious agreements related to its activities to develop and commercialize product candidates and utilize its technology platforms.&amp;#160;&amp;#160;Amounts earned by the Company in connection with these agreements totaled $393.7 million, $320.9 million, and $192.2 million in 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;Total Company-incurred expenses associated with these agreements, which include reimbursable and non-reimbursable amounts, an allocable portion of general and administrative costs, and cost-sharing of a collaborator&amp;#8217;s development expenses, where applicable (see Bayer HealthCare below), were $431.4 million, $333.7 million, and $230.6 million in 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;Significant agreements of this kind are described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&g
t;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 18pt"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;a.&amp;#160;&amp;#160;&amp;#160;The sanofi-aventis Group&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Aflibercept&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="D
ISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In September 2003, the Company entered into a collaboration agreement (the &amp;#8220;Aflibercept Agreement&amp;#8221;) with Aventis Pharmaceuticals Inc. (predecessor to sanofi-aventis U.S.), to jointly develop and commercialize aflibercept.&amp;#160;&amp;#160;In connection with this agreement, sanofi-aventis made a non-refundable up-front payment of $80.0 million and purchased 2,799,552 newly issued unregistered shares of the Company&amp;#8217;s Common Stock for $45.0 million.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In January 2005, the Company and sanofi-aventis amended the Aflibercept Agreem
ent to exclude intraocular delivery of aflibercept to the eye (&amp;#8220;Intraocular Delivery&amp;#8221;) from joint development under the agreement, and product rights to aflibercept in Intraocular Delivery reverted to Regeneron.&amp;#160;&amp;#160;In connection with this amendment, sanofi-aventis made a $25.0 million non-refundable payment to Regeneron (the &amp;#8220;Intraocular Termination Payment&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In December 2005, the Company and sanofi-aventis amended the Aflibercept Agreement to expand the territory in which the companies are collaborating on the development of aflibercept to include Japan.&amp;#160;&amp;#160;In connection with this amendment, sanofi-aventis agreed to make a $25.0 million non-refundable 
up-front payment to the Company, which was received in January 2006.&amp;#160;&amp;#160;Under the Aflibercept Agreement, as amended, the Company and sanofi-aventis will share co-promotion rights and profits on sales, if any, of aflibercept outside of Japan, for disease indications included in the companies&amp;#8217; collaboration.&amp;#160;&amp;#160;The Company is entitled to a royalty of approximately 35% on annual sales of aflibercept in Japan, subject to certain potential adjustments.&amp;#160;&amp;#160;The Company may also receive up to $400 million in milestone payments upon receipt of specified marketing approvals, including up to $360 million in milestone payments related to the receipt of marketing approvals for up to eight aflibercept oncology and other indications in the United States or the European Union and up to $40 million related to the receipt of marketing approvals for up to five aflibercept oncology indications in Japan.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 
0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Under the Aflibercept Agreement, as amended, agreed upon worldwide development expenses incurred by both companies during the term of the agreement will be funded by sanofi-aventis.&amp;#160;&amp;#160;If the collaboration becomes profitable, Regeneron will be obligated to reimburse sanofi-aventis for 50% of these development expenses, or half of $707.3 million as of December 31, 2010, in accordance with a formula based on the amount of development expenses and Regeneron&amp;#8217;s share of the collaboration profits and Japan royalties, or at a faster rate at Regeneron&amp;#8217;s option.&amp;#160;&amp;#160;Regeneron has the option to conduct additional pre-Phase III studies at its own expense.&amp;#160;&amp;#160;In connection with the January 2005 amendment to the Aflibercept Agreement, the
 Intraocular Termination Payment of $25.0 million will be considered an aflibercept development expense and will be subject to 50% reimbursement by Regeneron to sanofi-aventis, as described above, if the collaboration becomes profitable.&amp;#160;&amp;#160;In addition, if the first commercial sale of an aflibercept product in Intraocular Delivery predates the first commercial sale of an aflibercept product under the collaboration by two years, Regeneron will begin reimbursing sanofi-aventis for up to $7.5 million of aflibercept development expenses in accordance with a formula until the first commercial aflibercept sale under the collaboration occurs.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Sanofi-aventis has the right to terminate the agreement without cause with
 at least twelve months advance notice.&amp;#160;&amp;#160;Upon termination of the agreement for any reason, Regeneron&amp;#8217;s obligation to reimburse sanofi-aventis, for 50% of aflibercept development expenses will terminate, and the Company will retain all rights to aflibercept.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In accordance with the Company&amp;#8217;s revenue recognition policy described in Note 2, the up-front payments received in September 2003 and January 2006, of $80.0 million and $25.0 million, respectively, and reimbursement of Regeneron-incurred development expenses, are being recognized as collaboration revenue over the related performance period.&amp;#160;&amp;#160;During the fourth quarter of 2008, the Company shortened its estimated perfo
rmance period in connection with the $80.0 million and $25.0 million up-front payments from sanofi-aventis.&amp;#160;&amp;#160;The net effect of this change in the Company&amp;#8217;s estimate resulted in the recognition of an additional $1.2 million in collaboration revenue in 2010 and 2009, compared to amounts recognized in connection with these deferred payments in 2008.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company recognized $26.4 million, $36.5 million, and $44.4 million of collaboration development revenue in 2010, 2009, and 2008, respectively, in connection with the Aflibercept Agreement, as amended.&amp;#160;&amp;#160;At December 31, 2010 and 2009, amounts receivable from sanofi-aventis totaled $3.9 million and $3.6 million, respectively, and deferr
ed revenue was $32.6 million and $42.5 million, respectively, in connection with the Aflibercept Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;&lt;font style="MARGIN-LEFT: 18pt"&gt;&lt;/font&gt;Antibodies&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In November 2007, the Company entered into a global, strategic collaboration (the &amp;#8220;Antibody Collaboration&amp;#8221;) with sanofi-aventis to discover, develop, and commercialize fully human monoclonal antibodies&lt;font style="DISPLAY: inline; FO
NT-STYLE: italic"&gt;.&amp;#160;&amp;#160;&lt;/font&gt;In connection with the collaboration, in December 2007, sanofi-aventis purchased 12 million newly issued, unregistered shares of the Company&amp;#8217;s Common Stock for $312.0 million (see Note 12).&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Antibody Collaboration is governed by a Discovery and Preclinical Development Agreement (the &amp;#8220;Discovery Agreement&amp;#8221;) and a License and Collaboration Agreement (the &amp;#8220;License Agreement&amp;#8221;).&amp;#160;&amp;#160;The Company received a non-refundable up-front payment of $85.0 million from sanofi-aventis under the Discovery Agreement.&amp;#160;&amp;#160;In addition, under the Discovery Agreement, sanofi-aventis is funding&amp;#160;&amp;#160;
the Company&amp;#8217;s research to identify and validate potential drug discovery targets and develop fully human monoclonal antibodies against these targets.&amp;#160;&amp;#160;Sanofi-aventis funded $174.5 million of such research from the collaboration&amp;#8217;s inception through December 31, 2009.&amp;#160;&amp;#160;In November 2009, the Company and sanofi-aventis amended these collaboration agreements to expand and extend the Antibody Collaboration.&amp;#160;&amp;#160;Pursuant to the Discovery Agreement, as amended, sanofi-aventis agreed to fund up to $160 million per year of the Company&amp;#8217;s research activities in 2010 through 2017, subject to a one-time option for sanofi-aventis to adjust the maximum reimbursement amount down to $120 million per year commencing in 2014 if over the prior two years certain specified criteria were not satisfied.&amp;#160;&amp;#160;In 2010, as the Company scaled up its capacity to conduct antibody discovery activities, sanofi-aventis funded $137.7 million of the 
Company&amp;#8217;s preclinical research under the amended Discovery Agreement.&amp;#160;&amp;#160;The balance between that amount and $160 million, or $22.3 million, has been added to the funding otherwise available to the Company in 2011-2012 under the amended Discovery Agreement.&amp;#160;&amp;#160;The amended Discovery Agreement will expire on December 31, 2017; however, sanofi-aventis has an option to extend the agreement for up to an additional three years for further antibody development and preclinical activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For each drug candidate identified under the Discovery Agreement, sanofi-aventis has the option to license rights to the candidate under the License Agreement.&amp;#160;&amp;#160;If it elects to do so, sano
fi-aventis will co-develop the drug candidate with the Company through product approval.&amp;#160;&amp;#160;If sanofi-aventis does not exercise its option to license rights to a particular drug candidate under the License Agreement, the Company retains the exclusive right to develop and commercialize such drug candidate, and sanofi-aventis will receive a royalty on sales, if any.&amp;#160;&amp;#160;The Company and sanofi-aventis are currently co-developing eight therapeutic antibodies under the License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Under the License Agreement, agreed upon worldwide development expenses incurred by both companies during the term of the agreement are funded by sanofi-aventis, except that following receipt of the first positive P
hase 3 trial results for a co-developed drug candidate, subsequent Phase 3 trial-related costs for that drug candidate (&amp;#8220;Shared Phase 3 Trial Costs&amp;#8221;) are shared 80% by sanofi-aventis and 20% by Regeneron.&amp;#160;&amp;#160;If the Antibody Collaboration becomes profitable, Regeneron will be obligated to reimburse sanofi-aventis for 50% of development expenses that were fully funded by sanofi-aventis (or half of $341.0 million as of December 31, 2010) and 30% of Shared Phase 3 Trial Costs, in accordance with a defined formula based on the amounts of these expenses and the Company&amp;#8217;s share of collaboration profits from commercialization of collaboration products.&amp;#160;&amp;#160;&amp;#160;However, the Company is not required to apply more than 10% of its share of the profits from the antibody collaboration in any calendar quarter to reimburse sanofi-aventis for these development costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/d
iv&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Sanofi-aventis will lead commercialization activities for products developed under the License Agreement, subject to the Company&amp;#8217;s right to co-promote such products.&amp;#160;&amp;#160;The parties will equally share profits and losses from sales within the United States.&amp;#160;&amp;#160;The parties will share profits outside the United States on a sliding scale based on sales starting at 65% (sanofi-aventis)/35% (Regeneron) and ending at 55% (sanofi-aventis)/45% (Regeneron), and losses outside the United States at 55% (sanofi-aventis)/45% (Regeneron).&amp;#160;&amp;#160;In addition to profit sharing, the Company is entitled to receive up to $250 million in sales milestone payments, with milestone payments commencing only if and after aggregate annual sales outside the United States exceed $1.0 billion on
 a rolling 12-month basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Regeneron is obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the Antibody Collaboration until commercial supplies of that drug candidate are being manufactured.&amp;#160;&amp;#160;In connection with the November 2009 amendment of the collaboration&amp;#8217;s Discovery Agreement, sanofi-aventis is funding up to $30 million of agreed-upon costs incurred by the Company to expand its manufacturing capacity at the Company&amp;#8217;s Rensselaer, New York facilities, of which $23.4 million has been received or is receivable at December 31, 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&g
t;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;With respect to each antibody product which enters development under the License Agreement, sanofi-aventis or the Company may, by giving twelve months notice, opt-out of further development and/or commercialization of the product, in which event the other party retains exclusive rights to continue the development and/or commercialization of the product.&amp;#160;&amp;#160;The Company may also opt-out of the further development of an antibody product if it gives notice to sanofi-aventis within thirty days of the date that sanofi-aventis enters joint development of such antibody product under the License Agreement.&amp;#160;&amp;#160;Each of the Discovery Agreement and the License Agreement contains other termination provisions, including for material breach by the other party.&amp;#160;&amp;#160;Prior to December 31, 2017
, sanofi-aventis has the right to terminate the amended Discovery Agreement without cause with at least three months advance written notice; however, except under defined circumstances, sanofi-aventis would be obligated to immediately pay to the Company the full amount of unpaid research funding during the remaining term of the research agreement through December 31, 2017.&amp;#160;&amp;#160;Upon termination of the collaboration in its entirety, the Company&amp;#8217;s obligation to reimburse sanofi-aventis for development costs out of any future profits from collaboration products will terminate.&amp;#160;&amp;#160;Upon expiration of the amended Discovery Agreement, sanofi-aventis has an option to license the Company&amp;#8217;s &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelocImmune&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"&gt;&amp;#210;&lt;/font&gt; technology for agreed upon consideration.&lt;/font&gt;&lt;/div&gt;&lt;div
 style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In connection with the Antibody Collaboration, in August 2008, the Company entered into a separate agreement with sanofi-aventis to use Regeneron's proprietary &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"&gt;&amp;#210;&lt;/font&gt; technology platform to supply sanofi-aventis with genetically modified mammalian models of gene function and disease (the &amp;#8220;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"&gt;&amp;#174;&lt;/font&gt; Agreement&amp;#8221;)&lt;font style="DISPLAY: inline; FONT-STY
LE: italic"&gt;.&lt;/font&gt;&amp;#160;&amp;#160;The &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"&gt;&amp;#174;&lt;/font&gt; Agreement provides for minimum annual order quantities for the term of the agreement, which extends through December 2012, for which the Company expects to receive payments totaling a minimum of $21.5 million.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In accordance with the Company&amp;#8217;s revenue recognition policy described in Note 2, the (i) $85.0 million up-front payment received in December 2007, (ii) reimbursement of Regeneron-incurred expenses under the Discovery and License Agreements, (iii) $21.5 million
 of aggregate minimum payments under the &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"&gt;&amp;#174;&lt;/font&gt; Agreement, and (iv) reimbursement of agreed-upon costs to expand the Company&amp;#8217;s manufacturing capacity are being recognized as collaboration revenue over the related performance period.&amp;#160;&amp;#160;In connection with the amendments to expand and extend the Company&amp;#8217;s antibody collaboration with sanofi-aventis, during the fourth quarter of 2009, the Company extended its estimated performance period related to the $85.0 million up-front payment received from sanofi-aventis under the Discovery Agreement and the $21.5 million of aggregate minimum payments under the &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"&gt;&amp;#174;&
lt;/font&gt; Agreement&amp;#160;&amp;#160;&amp;#160;The effect of this change in estimate resulted in the recognition of $5.3 million less in collaboration revenue in 2010, compared to 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In connection with the Antibody Collaboration, the Company recognized $284.9 million, $210.7 million, and $109.6 million of collaboration revenue in 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;In addition, at December 31, 2010 and 2009, amounts receivable from sanofi-aventis totaled $75.7 million and $59.1 million and deferred revenue was $84.0 million and $66.0 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpad
ding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 18pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;b.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;Bayer HealthCare LLC&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In October 2006, the Company entered into a license and collaboration agreement with Bayer HealthCare LLC t
o globally develop, and commercialize outside the United States, the Company&amp;#8217;s VEGF Trap for the treatment of eye disease by local administration (&amp;#8220;VEGF Trap-Eye&amp;#8221;).&amp;#160;&amp;#160;Under the terms of the agreement, Bayer HealthCare made a non-refundable up-front payment to the Company of $75.0 million.&amp;#160;&amp;#160;In August 2007, the Company received a $20.0 million milestone payment from Bayer HealthCare (which, for the purpose of revenue recognition, was not considered substantive) following dosing of the first patient in a Phase 3 study of VEGF Trap-Eye in the neovascular form of age-related macular degeneration (&amp;#8220;wet AMD&amp;#8221;).&amp;#160;&amp;#160;In July 2009, the Company received a $20.0 million milestone payment from Bayer HealthCare following dosing of the first patient in a Phase 3 study of VEGF Trap-Eye in Central Retinal Vein Occlusion (&amp;#8220;CRVO&amp;#8221;).&amp;#160;&amp;#160;In the fourth quarter of 2010, the Company earned two $10.0 
million substantive milestone payments (for a total of $20.0 million) from Bayer HealthCare for achieving positive 52-week results in the Phase 3 study of VEGF Trap-Eye in wet AMD and positive 6-month results in the Phase 3 study of VEGF Trap-Eye in CRVO.&amp;#160;&amp;#160;One of these $10.0 million payments was received in December 2010 and the other $10.0 million payment was received in January 2011.&amp;#160;&amp;#160;The Company is eligible to receive up to $50 million in future milestone payments related to marketing approvals of VEGF Trap-Eye in major market countries outside the United States.&amp;#160;&amp;#160;The Company is also eligible to receive up to $135 million in sales milestone payments when and if total annual sales of VEGF Trap-Eye outside the United States achieve certain specified levels starting at $200 million.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-
RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company will share equally with Bayer HealthCare in any future profits arising from the commercialization of VEGF Trap-Eye outside the United States.&amp;#160;&amp;#160;If VEGF Trap-Eye is granted marketing authorization in a major market country outside the United States and the collaboration becomes profitable, the Company will be obligated to reimburse Bayer HealthCare out of its share of the collaboration profits for 50% of the agreed upon development expenses that Bayer HealthCare has incurred (or half of $241.2 million as of December 31, 2010) in accordance with a formula based on the amount of development expenses that Bayer HealthCare has incurred and the Company&amp;#8217;s share of the collaboration profits, or at a faster rate at the Company&amp;#8217;s option.&amp;#160;&amp;#160;Within the United States, the Company is responsible for any future commercialization of VEGF Trap-Eye 
and retains exclusive rights to any future profits from such commercialization in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In 2008, the first $70.0 million of agreed upon VEGF Trap-Eye development expenses incurred by both companies, under a global development plan, were shared equally and the Company was solely responsible for up to the next $30.0 million of development expenses.&amp;#160;&amp;#160;In 2009 and thereafter, all development expenses are being shared equally.&amp;#160;&amp;#160;The Company is also obligated to use commercially reasonable efforts to supply clinical and commercial product requirements.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MAR
GIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Bayer HealthCare has the right to terminate the Bayer Agreement without cause with at least six months or twelve months advance notice depending on defined circumstances at the time of termination.&amp;#160;&amp;#160;In the event of termination of the agreement for any reason, the Company retains all rights to VEGF Trap-Eye.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The $75.0 million up-front licensing payment and the $20.0 million milestone payment received in August 2007 from Bayer HealthCare are being recognized as collaboration revenue over the related estimated performance period in accordance with the Compan
y&amp;#8217;s revenue recognition policy as described in Note 2.&amp;#160;&amp;#160;During the fourth quarter of 2008, the Company extended the estimated performance period in connection with these up-front and non-substantive milestone payments, which resulted in the recognition of $2.5 million less in collaboration revenue in 2009 and 2010, compared to amounts recognized in connection with these deferred payments in 2008.&amp;#160;&amp;#160;In periods when the Company recognizes VEGF Trap-Eye development expenses that the Company incurs under the collaboration, the Company also recognizes, as collaboration revenue, the portion of those VEGF Trap-Eye development expenses that is reimbursable from Bayer HealthCare.&amp;#160;&amp;#160;In periods when Bayer HealthCare incurs agreed upon VEGF Trap-Eye development expenses that benefit the collaboration and Regeneron, the Company also recognizes, as additional research and development expense, the portion of Bayer HealthCare&amp;#8217;s VEGF Trap-Eye development
 expenses that the Company is obligated to reimburse.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The Company recognized $75.4 million, $67.3 million, and $31.2 million of collaboration revenue from Bayer HealthCare in 2010, 2009, and 2008, respectively.&amp;#160;&amp;#160;In both 2010 and 2009, collaboration revenue from Bayer HealthCare included $20.0 million in milestone payments, as described above, which, for the purpose of revenue recognition, were considered substantive.&amp;#160;&amp;#160;In addition, in 2010, 2009, and 2008, the Company recognized as additional research and development expense $48.9 million, $37.7 million, and $30.0 million, respectively, of VEGF Trap-Eye development expenses that the Company was obligated to reimburse to Bayer HealthCare.&lt
;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;At December 31, 2010, one $10.0 million milestone payment was receivable from Bayer HealthCare, as described above.&amp;#160;&amp;#160;In connection with cost-sharing of VEGF Trap-Eye expenses under the collaboration, $2.3 million and $1.2 million was payable to Bayer HealthCare at December 31, 2010 and 2009, respectively.&amp;#160;&amp;#160;In addition, at December 31, 2010 and 2009, deferred revenue from the Company&amp;#8217;s collaboration with Bayer HealthCare was $47.0 million and $56.8 million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&l
t;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"&gt;&lt;tr valign="top"&gt;&lt;td style="WIDTH: 18pt" align="right"&gt;&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;c.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;National Institute of Health&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align=
"justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In September 2006, the Company was awarded a grant from the National Institutes of Health (&amp;#8220;NIH&amp;#8221;) as part of the NIH&amp;#8217;s Knockout Mouse Project.&amp;#160;&amp;#160;As amended, the NIH grant provides a minimum of $25.3 million in funding over a five-year period, including $1.5 million in funding to optimize certain existing technology, subject to compliance with its terms and annual funding approvals, for the Company&amp;#8217;s use of its &lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;VelociGene&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"&gt;&amp;#174;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;&amp;#160;&lt;/font&gt;technology to generate a collection of targeting vectors and targeted mouse embryonic stem cells which can be used to produce knockout mice.&amp;#160;&amp;#160;The Company recor
ds revenue in connection with the NIH grant using a proportional performance model as it incurs expenses related to the grant, subject to the grant&amp;#8217;s terms and annual funding approvals.&amp;#160;&amp;#160;In 2010, 2009, and 2008, the Company recognized contract research revenue of $4.6 million, $5.5 million, and $4.9 million, respectively, from the NIH Grant.&lt;/font&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding unitRef="u001" decimals="0" contextRef="c00048">87777008</dei:EntityCommonStockSharesOutstanding>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c00041">Large Accelerated Filer</dei:EntityFilerCategory>
  <!--Change in net unrealized gain (loss) on marketable securities, net of tax effect-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax unitRef="u000" decimals="-5" contextRef="c00007">700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
  <!--Income tax (benefit) expense-->
  <us-gaap:IncomeTaxExpenseBenefit unitRef="u000" decimals="-3" contextRef="c00041">0</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income tax (benefit) expense-->
  <us-gaap:IncomeTaxExpenseBenefit unitRef="u000" decimals="-3" contextRef="c00007">-4122000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income tax (benefit) expense-->
  <us-gaap:IncomeTaxExpenseBenefit unitRef="u000" decimals="-3" contextRef="c00000">2351000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Accumulated other comprehensive income-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="u000" decimals="-3" contextRef="c00034">-2491000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive income-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="u000" decimals="-3" contextRef="c00021">1044000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Deferred revenue from sanofi-aventis-->
  <regn:DeferredRevenueFromRelatedPartyNoncurrent unitRef="u000" decimals="-3" contextRef="c00034">97081000</regn:DeferredRevenueFromRelatedPartyNoncurrent>
  <!--Deferred revenue from sanofi-aventis-->
  <regn:DeferredRevenueFromRelatedPartyNoncurrent unitRef="u000" decimals="-3" contextRef="c00021">90933000</regn:DeferredRevenueFromRelatedPartyNoncurrent>
  <!--Total current liabilities-->
  <us-gaap:LiabilitiesCurrent unitRef="u000" decimals="-3" contextRef="c00034">109056000</us-gaap:LiabilitiesCurrent>
  <!--Total current liabilities-->
  <us-gaap:LiabilitiesCurrent unitRef="u000" decimals="-3" contextRef="c00021">93575000</us-gaap:LiabilitiesCurrent>

</xbrl>
</XBRL>
